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Becoming pregnant and carrying to term is undeniably a very complicated process. 
Unfortunately, reproductive failure is widespread among many women globally. There are a 
plethora of problems that can lead to reproductive failure among women such as, but not limited 
to, sexually transmitted infections (STI), hormone imbalance, body weight, stress, alcohol, drug 
abuse, diets, and genetics. A novel culprit that is now associated with reproductive failure is 
exposure to endocrine disrupting chemicals (EDCs). These chemical compounds can interact with 
the endocrine systems in humans and animals by influencing hormone metabolism. EDCs can 
disrupt the synthesis, secretion, transport, binding, action, or elimination of hormones, including 
hormones that are responsible for behavior and fertility, resulting in severe consequences for the 
reproductive and endocrine systems. One group of EDCs which gained interest are phthalates. 
Phthalates are a family of chemicals that are colorless, odorless, have lipophilic properties, and 
low solubility in water. Phthalates are used as plasticizers and additives in a variety of products 
such as polyvinyl chloride (PVC), cosmetics, adhesives, flooring, and medical supplies. However, 
phthalates leach from these products and enter the environment.  Animals and humans are exposed 
to a variety of phthalates daily due to high production and leaching of phthalates. 
Phthalates are classified as reproductive toxicants because have they been shown to impair 
normal reproduction function in males and females. However, studies have primarily focused on 
male reproduction. Studies have shown that phthalates are detected in both female reproductive 
organs and fluids. Measurable amounts of phthalates are present in human blood, urine, amniotic 
fluid, ovarian follicular fluid, breast milk, and umbilical cord blood. However, there is limited 
research on the effects of phthalates on the female reproduction system, including the uterus. 
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Specifically, it is unknown if environmentally and occupationally relevant doses of phthalates 
affect uterine morphology and function. Also, there are limited studies on the effects of phthalates 
on preimplantation embryos. Of these studies, most have shown that exposure to a single phthalate 
such as Di (2-ethylhexyl) phthalate (DEHP) and other EDCs have adverse effects on proper 
embryo development. However, there are limited data on the effects of exposure to relevant 
phthalate mixtures on preimplantation embryos. 
In this dissertation, I first examined whether adult exposure to environmentally and 
occupationally relevant doses of di (2-ethylhexyl) phthalate (DEHP) for 30 days in vivo alters 
uterine function and morphology. To determine whether the uterus was affected, the morphology, 
cellular proliferation, uterine glands, and steroid hormone levels were analyzed after exposure to 
DEHP for 30 days. Uterine morphology was evaluated by measuring the thickness of the 
myometrial layers (inner and outer), luminal epithelium height, counting the number of glands and 
finding the percentage of proliferating cells within the uterus. The results from this study 
demonstrated that exposure to DEHP decreased cellular proliferation in the luminal epithelium; 
however, increased cellular proliferation of the stromal cells. I also observed that exposure to an 
occupational dose of DEHP for 30 days increased the total number of glands present in the uterus. 
Exposure to DEHP for 30 days dilated blood vessels in the endometrium at both environmental 
and occupational doses. However, DEHP exposure did not cause any significant difference in the 
myometrial layers or luminal epithelium layer compared to control. Also, DEHP exposure for 30 
days did not alter sex steroid levels. These results demonstrate that exposure to specific doses of 
DEHP for 30 days can have adverse effects on reproductive function of the uterus. 
Lastly, in my dissertation, I examined whether relevant phthalate mixture altered 
preimplantation embryo development. The mixture used in this study is composed of the following 
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chemicals: 35% diethyl phthalate (DEP), 21% di (2-ethylhexyl) phthalate (DEHP), 15% di-n-butyl 
phthalate (DBP), 15% di-isononyl phthalate (DiNP), 8% di-isobutyl phthalate (DiBP), and 5% 
benzyl butyl phthalate (BBzP). Theses phthalates and percentages were from measurements 
obtained from pregnant women in the UIUC iKids study. To determine whether exposure to a 
phthalate mixture affects preimplantation and embryo development, embryos exposed to vehicle 
or mixture were observed at the 2-cell, 8-cell, morula, blastocyst, and hatched blastocyst stages. 
Also, embryo fragmentation was assessed. Oct-4 expression (4 cell stage), E-cadherin (8-cell and 
blastocyst), micronucleation (4-cell, 8-cell, blastocyst), and blastocyst cell populations of the inner 
cell mass (ICM) and trophectoderm (TE) was analyzed by immunofluorescence (IF) staining to 
observe protein expression and accurately count the number of ICM and TE cells within the 
blastocyst. The results from this study show that exposure to a relevant phthalate mixture greatly 
reduces the percentage of embryos which developed to the hatched blastocyst stage, increased 
fragmentation, increased Oct-4 expression, and reduced E-cadherin expression at the 8-cell stage 
and increased the percentage of micronucleation at the 4-cell stage. The results demonstrate that 
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Chapter 1: Introduction and Background 
  
Reproductive failure is widespread among many women, globally [1, 2, 3]. Identifying the 
probable causes of reproductive failure is of significant concern and it is continuously being 
investigated. One environmental aspect that is associated with reproductive failure is exposure to 
endocrine disrupting chemicals (EDCs), as humans are exposed to them daily. EDCs are chemical 
compounds that can interact with the endocrine system of humans and animals by influencing 
hormone metabolism (Figure 1) [4, 5, 6]. EDCs can disrupt the synthesis, secretion, transport, 
binding action or elimination of hormone response, including those that are responsible for 
behavior and fertility, resulting in severe consequences for the reproductive and endocrine systems 
[7]. 
 One group of EDCs which has gained increased interest is phthalates. Phthalates are a 
family of structurally related chemicals used as plasticizers and additives in a variety of products 
such as polyvinyl chloride (PVC), cosmetics, adhesives, flooring, and medical supplies [8, 9, 10]. 
Although phthalates are useful and have low productions cost, they readily leach from products 
and can enter biological tissues. Due to high usage and human exposure, phthalates have become 
a significant health concern because they are known EDCs and reproductive toxicants due to their 
structural similarity to hormones present in humans and animals. One of the more widely utilized 
phthalates di-(2-ethylhexyl) phthalate (DEHP) is associated with reproductive effects [11, 12, 13, 
14, 15].  
Studies have documented that phthalates such as DEHP can alter and impair reproductive 
homeostasis in both males and females [16, 17]. Although such findings are critical to better 
understand health effects due to exposure to phthalates, many studies routinely utilized a single 
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phthalate at extremely high doses, which are not environmentally or occupationally relevant-often 
over 100 times higher than human daily exposure levels [18]. Furthermore, studies have 
documented that humans and animals are exposed to a variety of phthalates daily. However, 
studies investigating phthalate mixtures have not used representative mixtures based on actual 
phthalates present in humans [19]. Given the pervasive nature of phthalates and daily human 
exposure, it is imperative to determine whether relevant environmental and occupational levels of 
phthalate exposure affect the uterus. Furthermore, it is imperative to determine whether exposure 
to a relevant phthalate mixture impact preimplantation embryo development. 
1.1 Phthalates 
Phthalates are a family of chemicals that are colorless, odorless, have lipophilic properties, 
and low solubility in water. There are two different categories of phthalates, based on high and 
low molecular weights. The molecular weights attribute to the number of carbon atoms present on 
the structural backbone. High molecular phthalates have more than five carbon atoms present, 
whereas low molecular weight phthalates have only 1-4 carbon atoms [20, 21]. 
 Phthalates are routinely used in the production of polyvinyl chloride (PVC) plastics and 
act as plasticizers to increase the flexibility, transparency, durability, and longevity of products. 
Such products include cosmetics, medical tubing, food containers, beverage containers, children’s 
toys, flooring, and clothing [8, 9, 10, 22]. Due to the variety of products that contain phthalates, 
production of phthalates is exceptionally high. One of the most widely utilized phthalates in PVC 
products, found in nearly 40% of plastics, is di-(2-ethylhexyl) phthalate (DEHP) [23].  
Approximately 18 billion tons of di-(2-ethylhexyl) phthalate (DEHP) alone are produced annually 
worldwide. Indeed, a study by Halden et al. 2007 [24] reported that approximately two million 
pounds of DEHP are produced in the United States annually. Along with DEHP, several other 
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phthalates are widely utilized, in many of the same products, such as dibutyl phthalate (DBP), di 
(2-ethylhexyl) phthalate (DEHP), diethyl phthalate (DEP), diisononyl phthalate (DiNP), diisobutyl 
phthalate (DiBP), and benzyl butyl phthalate (BBzP).  
Although phthalates are beneficial for plastic production and other products, they are non-
covalently bound to plastic, thus causing them to leach from products that are repeatedly heated 
and cleaned [13].  Due to leaching from plastic products, large quantities of phthalates are present 
at various dose ranges in environmental sources/resources such as the atmosphere, sediments, 
soil(s), and bodies of water [25, 26, 27]. It has been reported that phthalates can contaminate crop 
plants and soils. Studies have shown that when plants uptake soil nutrients pollutants such as 
phthalates are also taken up through their root systems. Studies have analyzed crops and revealed 
that phthalates are present in every plant organ including roots, stem, and seeds [28, 29, 30, 31] 
Due to the pervasive nature of phthalates, humans and other organisms are regularly 
exposed to phthalates at all ages and stages of life in both sexes (female and male) through dermal 
contact, ingestion, and inhalation. It is also extremely probable that populations located in areas 
where high production or usage of phthalates occurs, or individuals in certain occupations, may be 
exposed to levels that exceed what the EPA deems as the reference dose range of- 3–30 μg/kg/day 
[32]. Exposure to phthalates in some environments and occupation are slightly higher or three 
times higher than the recommended exposure. One study showed that cosmetics sales clerks had 
significantly higher presences of phthalates post-shift compared to pre-shift with doses levels at 
53.3 μg/g for MEHP post-shift compared to 30.9 μg/g for MEHP pre-shift [33].  Other 
occupational studies reported exposure to DEHP and DEP in 340,000 workers at levels ranging 
from 143-286 µg/kg/day [34]. Also, an expert panel estimated that newborns undergoing specific 
medical procedures are exposed to DEHP levels ranging from 130 to 6000 µg/kg BW/day [35]. 
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 Due to the high usage rate and ability to leach, phthalates such as DEHP and its associated 
metabolite mono-(2-ethylhexyl), MEHP, have been recognized as one of the most common 
environmental contaminants in human bodily fluids and tissues. Studies have reported that DEHP 
and MEHP are detectable in human bodily fluids, with almost 100% of tested human urine samples 
showing the presence of DEHP and MEHP. Both DEHP and MEHP are present in over 95% of 
human blood samples [36]. Furthermore, DEHP and MEHP are present in approximately 90–100% 
of amniotic fluid samples from second-trimester fetuses [37 & 38] as well as in breast milk [39], 
umbilical cord blood [40] and in ovarian follicular fluid [41]. 
The effects of exposure to DEHP or MEHP on female reproduction is an active area of 
investigation. In studies by Hannon et al. [42, 43], it was reported that DEHP exposure for 10 or 
30 days in adult mice disrupted ovarian function, potentially causing infertility and premature 
ovarian failure. The results indicated that lower levels of DEHP, levels within the range of human 
exposure, altered estrous cyclicity, and accelerated primordial follicle recruitment by 
dysregulating phosphatidylinositol 3-kinase (PI3K) signaling. These alterations were also 
observed at higher doses but to a lesser degree. Also, DEHP exposure for 30 days increased the 
percentage of time that the mice were in estrus. This study concluded that the decrease in 
primordial follicles accompanied by an increase in primary follicles after DEHP exposure 
accelerated follicle recruitment in vivo. Since females are born with a finite number of primordial 
follicles, acceleration of follicle depletion could eventually cause infertility [44, 45]. 
These studies focused primarily on ovarian effects and did not investigate the effects of 
DEHP on the uterus. In addition, another study suggested that DEHP reduces endometrial 
receptivity and impaired embryo implantation. However, the doses used exceeded environmental 
and occupational levels 1000mg/kg/day of DEHP [18]. Studies utilizing other commonly used 
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phthalates observed similar findings along with abortions, delayed pregnancy, altered estrous 
cyclicity, alterations of folliculogenesis, and oocyte development [42, 43, 44, 45]. Due to these 
findings, studies have begun investigating the effects of phthalate exposure on preimplantation 
embryos.    
Studies have documented that exposure to single EDC on preimplantation embryos (zygote 
to hatching blastocyst) have deleterious effects [46]. Chu et al., 2013 [47] reported that 
preimplantation embryos exposed to 10-3 M MEHP induced 2-cell embryo block and decreased 
heat shock cognate 70 (Hsc70), murine endogenous retrovirus (MuERV‐L) mRNA level, and Sox2 
protein levels. However, exposure markedly increased heat shock protein 70 (Hsp70.1), eukaryotic 
translation initiation factor-1A (eIF‐1A), zinc finger and SCAN domain containing 4 (Zscan4) 
mRNA level, and Oct4 protein level at the 2‐cell and 4‐cell stage. Another study documented that 
preimplantation embryo exposed to bisphenol A (BPA) affects embryo transport, development of 
preimplantation embryos, and the establishment of uterine receptivity of exposed dams [48]. 
Furthermore, Zhang et al. [49] documented that newborn female mice injected with DEHP at doses 
of 20 and 40 μg/kg per body weight following weaning had increased metaphase II spindle 
abnormalities and integrity of oocytes. 
 Although these studies are critical, it is also essential to investigate relevant phthalate 
mixtures and its effects on female reproduction. Zhou et al., [50] documented that female mice 
born to CD-1 (mice) dams exposed to a relevant phthalate mixture (20 and 200 μg/kg/day, 200 and 
500 mg/kg/day) daily from gestational day 10 to birth had deleterious effects. Exposure to a 
relevant phthalate mixture increased uterine weight, breeding complications, abnormal cyclicity, 
and reduced fertility-related indices due to parental exposure to phthalate mixture. Given these 
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findings, it is critical to investigate the effects of a relevant phthalate mixture on, preimplantation 
embryo development and gene expression. 
1.2 Uterus           
 The uterus is one of the largest organs in the female reproductive tract, the uterus is 
significant during the menstrual cycle and is an essential environment for embryo implantation 
and fetal development. The uterus is hollowed pear-shaped organ that has smooth muscular 
walls. The uterus is relatively active during the menstrual cycle; however, during pregnancy, the 
uterus is quiescent while the fetus is developing and increasing in size within the uterine 
environment. As the fetus is growing the muscular walls of the uterus, begin to expand [51, 52]. 
In contrast, at the time of labor, the quiescent state it is converted to a very active and reactive 
state, characterized by forceful, rhythmic, and synchronous contractility.  
The uterus is composed of several different components that have distinctive roles during 
the menstrual cycle and pregnancy. These components are the myometrium, endometrium, 
lumen, and uterine glands [Figure 2].  
 The myometrium contains a longitudinal outer and inner layer, which in combination 
maintains the structural integrity of the uterus. The outer layer, the serosa, is a thin layer that covers 
most of the uterus. The inner layer consists predominantly of smooth muscle cells and contains 
blood and lymph vessels, nerves, immune cells, and connective tissue. The inner layer is also 
essential in embryo spacing in multi-bearing species [53]. The myometrium is composed of mainly 
smooth muscles cells, allowing for the expansion of the layers during pregnancy. Throughout the 
myometrium layer, progesterone receptors (PR) that, when stimulated, mediate progesterone-
dependent signaling and connects to a network of pathways for regulation of contractility 
responses in myometrium during parturition (birthing) [54].  
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The endometrium resides under the inner myometrial layer. The endometrium is a 
specialized mucosal layer that is primarily composed of uterine glands, highly cellular stroma and 
luminal epithelium (LE), which lies in the center of the uterus. The endometrium undergoes 
cyclical changes of growth, differentiation, reabsorption, or shedding in response to the tightly 
controlled variations in ovarian sex steroids throughout the reproductive life [55]. During the 
menstrual cycle, the endometrium changes and exhibits a short period of embryo receptivity, 
known as the “implantation window” [55, 56]. Embryo receptivity timing is extremely critical for 
a successful pregnancy. The arrival of a hatched blastocyst(s) and receptivity must be in sync, if 
not the hatched embryo(s) will be unable to implant, thus resulting in a failed pregnancy.  
The luminal epithelium (LE) is composed of a simple single layer of tall columnar cells 
containing estrogen receptor alpha (ERα). When estrogen (E2) is present, it binds to these receptors 
activating cellular proliferation.   Before implantation, the luminal epithelium undergoes steroid 
hormone-induced structural and functional changes that render it competent for embryo 
attachment. Before implantation occurs, the LE will begin to elongate forming channels comprised 
of the columnar cells which grow into the endometrium and pinch off in small circular structures 
which establish uterine glands.  
Uterine glands are composed of structured columnar cells due to being produced by the LE 
and are located within the endometrium. Upon conception, the uterine glands are essential for the 
survival of the fetus. The primary role of the uterine glands is to synthesize and secrete essential 
substances (nutrients, growth factors, and cytokines) for survival and development of the 
conceptus (embryo/fetus and associated extraembryonic membranes) [57, 58, 62]. The lack of 
uterine glands causes pregnancy failure and complications in both animals and humans [58, 59]. 
In chapter 2, I will investigate the morphological features of the uterus, cellular proliferation, blood 
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vessels, and the presence of uterine glands of female mice exposed to relevant levels of DEHP for 
30 days. 
1.3 Preimplantation Embryos 
Mammalian embryo development initiates after oocyte fertilization. When fertilization is 
successful, oocytes will exit arrest and develop into an embryo, which then produces viable 
offspring. However, one phase that is overlooked in the success of viable offspring is 
preimplantation embryo(s) development. Preimplantation embryo development is regarded as the 
period before embryos implant into the uterus. During this phase of development, the zygote will 
undergo several rounds of cleavage/division to transition into a hatching blastocyst, which is 
capable of implanting into the uterus and developing into a viable fetus.  
Preimplantation embryos undergo an array of complex morphological changes controlled 
by genetic regulatory networks [60]. Many, genetic regulatory networks are involved in the 
expression of genes (depending on the species) that are activated and degraded during certain 
stages of development [61, 62]. The genes expressed during each phase are critical for a zygote to 
develop to the blastocyst stage that will implant in the uterus successfully during endometrial 
receptivity. The timing in which each phase occurs, and the genes expressed are mainly dependent 
on species [63]. Although preimplantation embryo development is intensively investigated, it is 
challenging to obtain human preimplantation embryos due to ethical reasons (depending on the 
country) and obtaining sufficient viable samples for research as well. As an alternative, non-human 
primates and domestic animals have been utilized to investigate preimplantation embryo 
development [64, 65, 66]. Of all the readily available mammalian preimplantation embryo models, 
most investigators utilize mice, as they are inexpensive, easy to manipulate genetically and provide 
a quintessential model for studying these events in the human preimplantation embryo [66, 67]. 
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Although human embryos transition through developmental stages later than with mouse embryos, 
both human and mouse embryos ultimately have similar gene expression and produce the same 
cell lineages. [Figure 3]66. 
 After fertilization, the zygote undergoes a complex series of events that is dependent on 
several components. During the initial stage of development, maternal mRNAs assist the zygote 
development, and initial proteins are stored that are used as nutrients [63, 68, 69].  In mice, the 
formation of the 2-cell embryo occurs at day 1.5 (initial cleavage) and signifies the transition from 
maternal mRNAs to zygotic independence [68, 70]. The degradation of maternal mRNAs initiated 
by meiotic maturation and is approximately 90% completed within the late 2-cell stage of the 
mouse [63, 66, 67]. Once the embryos reach the 8-cell stage, they undergo compactions. During 
this stage, the presence of cadherin junctions enables cell-to-cell adhesion of blastomeres, thus 
forming a compacted morula [66, 71, 72, 73]. As the morula, transitions to the early blastocyst 
stage by the initial secretion between the morula cells creating a cavity, this small cavity is then 
maintained and increased by actions of the membrane channels Na/K-ATPase that raise the salt 
concentration within the embryo, attracting water through osmosis [74, 75]. As this cavity fills, 
the blastocyst enlarges and enters the late blastocyst stage, and begins to undergo repeated 
contractions all while the protective zona pellucida membrane begins to thin. The hatching process 
is thought to be enabled by prostaglandin I2 (PGI2 or prostacyclin), one of the factors produced 
by the uterus via the cyclooxygenase-2 (cox-2) pathway, plays a crucial role in embryo 





 Specific Genes and Their Function 
During development, several genes are activated and degraded at certain stages, however, 
there are several genes mostly responsible for the establishment of the two cell lineages- 
trophectoderm (TE) and inner cell mass (ICM). The cell lineage formation occurs by differential 
expression of several transcription factors; however, there are few which are essential in activating 
other downstream transcription genes such as; octamer-binding transcription factor 4 (OCT-4), 
caudal type homeobox 2 (CDX-2), and E-cadherin. These genes play a vital role in the 
development of the ICM and TE [79, 79, 80]. Generally, if these genes are altered during early 
development, the embryos will be sub-optimal for implantation or non-viable depending on the 
severity of dysregulation [78, 81].  
Oct-4 is a member of the POU-domain transcription factor family and is one of the most 
critical genes during embryo development. Oct-4 is required for primordial germ cell survival and 
considered the master regulator of pluripotency [78]. Oct-4 is present initially in the oocyte, and 
like many other maternal transcripts its expression declines upon the first cleavage, but it then 
reappears at the late 2-cell or 4-cell stage and is expressed in the blastomeres of the embryo. The 
expression of Oct-4 is restricted to pluripotent and totipotent cells, and its primary function is to 
regulate embryonic stem (ES) cell fate, through the promotion of constant self-renewal and 
interaction with other genes such as SOX-2. Studies have indicated that embryos with inactivated 
Oct-4 die at the time of implantation because they have trophoblast cells but lack pluripotent ICM 
cells [82, 83, 84]. Thus, Oct-4 is the master regulator of pluripotency. 
Cdx-2 is a member of the caudal-related homeobox transcription factor family. Cdx-2 is 
an essential gene for the development of the pre-implantation mammalian embryo and several 
stages after that. Initially, Cdx-2 is expressed during the morula stage when the cell types begin to 
11 
differentiate [79]. The increased level of Cdx-2 represses Oct-4 within perimeter blastomeres cells, 
thus resulting in Cdx-2 dominant cells. Embryos with zygotic deletion of Cdx-2 usually develop 
until the late blastocyst stage leading to the conclusion that Cdx-2 is involved only in the 
maintenance of the TE lineage [85, 86]. Results showed that the formation of the blastocyst 
occurred, and TE-like cells were present, but implantation did not occur as there is no actual TE 
present [85, 86].  Thus, during blastocyst development, Cdx-2 is essential for the establishment of 
the TE lineage and implantation. Also, studies have shown that the down-regulation of Cdx-2 
expression of the oocyte and zygote resulted in phenotypic effects on cell polarization, 
development arrest, and abnormal mitochondria activation in preimplantation embryos [87, 88]. 
Therefore, Cdx-2 plays a critical role in the successful formation and implantation of a viable 
blastocyst.   
E-cadherin is a member of the family known as cadherins, which is composed of over 100 
members of cell membrane-localized receptors with multiple extracellular cadherin repeats that 
are essential for proper adhesion among many cell types. Cadherin nomenclature derives from 
being a calcium-dependent adhesion molecule [89]. Within the cadherin family a subset, known 
as classical cadherins share a conserved cytoplasmic tail that binds catenins and binds to the actin 
cytoskeleton [90]. Of this subset, the more prominent of the cadherins are epithelial (E), neuronal 
(N) and vascular endothelial (VE)-cadherins which form adhesion with their respective cell types. 
E-cadherin has a particular role in preimplantation development. E-cadherin is a single-pass 
transmembrane glycoprotein containing five extracellular repeats that mediate its Ca2+ -dependent 
homophilic interaction with opposing molecules on neighboring cells (Figure 4)91 
E-cadherin is initially maternally derived in the oocyte, however as the embryo develops, 
E-cadherin synthesis occurs, and the embryo becomes self-regulated. Upregulation of E-cadherin 
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occurs at the 8-cell stage, when cell compaction is initiated, loosely aggregated blastomeres 
become tightly compacted ball of cells. During this process, E-cadherin is evenly dispersed among 
the compacting blastomeres; the lack of uneven distribution results in delayed or inhibited 
development [80]. The initiation of adhesion at the 8-cell stage directs the establishment of the 
first forms of cellular polarity, which is involved in cell fate of developing embryos [92]. Apical 
polarity complexes form on the outer cells and sequester components of the Hippo signaling 
pathway, preventing activation requirements for ICM establishments. This process occurs due to 
phosphorylated yes-associated protein (Yap) entering the nucleus and driving expression of the 
trophectoderm-specific gene Cdx2 and gate binding protein 3 (GATA3). However, phosphorylated 
Yap does not enter the nucleus, and the Hippo pathway is activated, allowing transcription of ICM-
specific genes. Embryos lacking zygotic E-cadherin are preimplantation lethal, meaning that, 
preimplantation embryos undergo compaction due to residual maternal E-cadherin but fail to form 
a blastocyst [93, 94].  
Čikoš, 2012 [95] reported that the preimplantation period of development is considered 
one of the most sensitive phases of mammalian development. Therefore, any disturbances of gene 
expression or energy metabolism during this phase of development can result in abnormal, 
delayed, or, lethal development of preimplantation embryos leading to poor pregnancy outcomes 
in humans and animals. Such aberration that may arise during development includes delay of 









  Fragmentation occurs when cell division occurs without nuclear division [96]. Primarily 
fragmentation is a phenomenon that occurs during cell division when portions of cytoplasm are 
enclosed by the cell membrane, but do not contain DNA, which occurs during cell division. 
Fragmentation is associated with irregular cell division and initiation of apoptosis in adjacent cells 
leading to disruption of blastulation [97, 98,99, 100, 101], and a loss of cytoplasmic volume that 
results in decreased implantation potential [100,105]. Therefore, fragmentation is an established 
marker of embryo viability. The degree of fragmentation also correlates with the overall viability 
of the embryo. The degree of fragmentation is expressed as the percentage of the total cytoplasmic 
volume and the severity of fragmentation, defined as mild (≤ 10%), moderate (10–25%) and severe 
(>25%) [100,106, 107, 108].  
Micronucleation 
 As preimplantation embryos develop, they undergo several rounds cleavage/division. 
Chromosomes within each blastomeres segregate, which is achieved by correct attachment of 
spindles to kinetochores, complex proteinaceous structures that assemble on centromeric DNA 
[109-112]. However, it is common that chromosomes do not attach properly. This phenomenon 
results in lagging chromosomes during anaphase, which correlates with chromosomally unstable 
cells resulting in the formation of micronuclei. Micronuclei are small nuclear fragments that form 
if the chromosome remains separate from the core chromosome once the nuclear envelope 
reorganizes [Figure 5]. Micronucleation it thought to occur due to genetic aberration from either 
maternal or paternal DNA, or due to exposure to chemicals causing genotoxicity [110].  
 Although micronucleation is common, the total percentage and frequency of 
micronucleation within cells of an embryo decease the viability. The presence of micronucleation 
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is associated with poor quality of preimplantation embryos. Although micronucleation is a reliable 
identifier of poor-quality preimplantation embryos, four possible outcomes exist for blastomeres 
that have micronuclei: degradation, extrusion, persistence, and reincorporation [110]. If 
degradation, extrusion or reincorporation of the micronuclei occurs within blastomeres(s) the 
embryo may continue to develop normally. However, micronuclei reincorporated into the DNA at 
the interphase stage causes rearrangement of DNA, resulting in chromothripsis [113]. However, if 
micronuclei or multinucleation (more than one micronuclei within a blastomeres) remains 
persistent, several outcomes can occur and be detrimental to the embryo such as apoptosis of the 
blastomeres(s), aneuploidy (misshapen or abnormal number of chromosomes) increased 
fragmentation, cellular arrest, decreased blastocyst development or reduced implantation [114, 
115, 116]. Based on the findings from chapter 2 that phthalates affect uterine functionality, we 
investigated the whether exposure to a relevant phthalate mixture impacts preimplantation embryo 
development. Specifically, I investigated the effects of a relevant phthalate mixture on 
preimplantation embryo development, protein expression, fragmentation, and micronucleation. 
1.4 Significance/Innovation 
  The experiments conducted in this research are significant and innovative because limited 
information exists on the effects of both environmentally and occupationally relevant doses of 
phthalates, including DEHP, on the adult uterus. Furthermore, limited studies have investigated 
the effects of relevant phthalate mixtures on preimplantation embryos. It is critical to investigate 
relevant doses of DEHP and phthalate mixtures due to constant exposure to numerous phthalates. 
The research described below used mouse models with exposure levels at doses that are both 
environmentally and occupationally relevant to humans. The main hypothesis of this study was 
that exposure to environmental or occupational doses of phthalate chemicals would have 
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deleterious effects on female uterine structure, function, and preimplantation embryo development 




















Figure 1.1. Hormones are naturally present within the body. When hormones bind to a hormone 
receptor, a cellular response occurs (left). An endocrine disruptor can mimic natural hormones 
causing a cellular response (middle) or inhibiting a cellular response (right). Kadeem A. 
















Figure 1.2. Hematoxylin and eosin staining of mouse uterus cross-section. Demonstration of layers 
and components within the uterus. Outer myometrium (O.Myo), inner myometrium (I.Myo), 
















Figure 1.3. (A) In the mouse, the fertilized egg undergoes three rounds of cleavage, producing an 
eight-cell embryo that then undergoes compaction. From the eight-cell stage onward, cell divisions 
produce two populations of cells, those that occupy the inside of the embryo and those that are 
located on the outside. The blastocoel cavity begins to form inside the embryo beginning at the 
32-cell stage and continues to expand as the embryo grows and matures into the late blastocyst 
stage. Cdx2 becomes upregulated in outside (future TE cells), starting at the 32-cell stage, while 
Oct4 expression becomes limited to the ICM in the early blastocyst stage. By the late blastocyst 
stage, the ICM contains a population of Nanog-positive EPI cells and a population of Gata6-
positive PE cells while continuing to express Oct4 ubiquitously. (B) Development is similar in the 
early human embryo, although compaction occurs at the 16-cell stage and the mutually exclusive 













Figure 1.4. Schematic representation of E-cadherin-mediated cell–cell adherens junctions and 
cell–ECM integrin-mediated adhesions. E-cadherin is a single-pass transmembrane protein, 
whose extracellular domain, which is composed of five Ca2+ -binding repeats (green squares), 
mediates specific homophilic interactions with neighboring cells. The intracellular domain of 
E-cadherin associates with catenins, which tether these complexes to the actin cytoskeleton 
forming stable adherin junctions (AJs). Focal adhesions are multi-protein complexes that 
mediate the contact of cells to the ECM (red lines); the membrane receptors for this type of 
adhesion are heterodimers of α- and β-integrins. They form multi-protein complexes that are 
linked to the actin cytoskeleton. Key players that link integrins to the actin cytoskeleton include 
talin, kindlins and α-actin. The tyrosine kinases focal adhesion kinase (FAK) and Src are also 









Figure 1.5. A schematic representation of micronucleation within embryo blastomeres at the 4-cell 
stage. (A) Under normal cellular division, chromosomes undergo segregation, which is achieved 
by correct attachment of spindle microtubules to kinetochores, complex proteinaceous structures 
that assemble centromeric DNA. This results in an absence of micronucleation. (B) Misattachment 
of the chromosome can cause a lagging chromosomes separation during the anaphase stage, 
leaving behind disassociated small fragments or micronuclei outside of the nuclear envelope. 
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Chapter 2: Di (2-Ethylhexyl) Phthalate (DEHP) Alter Proliferation And Uterine Glands 
Numbers In The Uteri Of Adult Exposed Mice 
2.1 Introduction 
Phthalates are a family of chemicals that are colorless, odorless, with lipophilic properties 
and low solubility in H2O. These chemicals are present in polyvinyl chloride (PVC) plastics and 
act as plasticizers to increase the flexibility, transparency, durability, and longevity of products 
such as cosmetics, medical tubing, food and beverage containers, children’s toys, flooring, and 
clothing [1]. The production of phthalates is exceptionally high, with approximately 18 billion tons 
produced annually worldwide. One of the most widely utilized phthalates in PVC products, found 
in nearly 40% of plastics, is di-(2-ethylhexyl) phthalate (DEHP) [2]. Indeed, a study by Halden [3] 
reported that approximately two million pounds of DEHP are produced in the United States 
annually. Although phthalates are beneficial to plastic production, they are non-covalently bound 
to plastic, causing them to readily leach into the environment from products that are repeatedly 
heated and cleaned [4]. Due to the leaching from plastic products, large quantities of phthalates 
have been detected at various dose ranges in environmental sources/resources such as the 
atmosphere, sediments, soil(s), and bodies of water [5,6,7]. 
With such high amounts of DEHP present in the environment, humans and other organisms 
are exposed to DEHP daily through inhalation, ingestion, and dermal contact. It is also extremely 
likely that populations located in areas where high production or usage of DEHP occurs, or 
individuals in certain occupations, may be exposed to levels that exceed what the EPA deems as 
the reference dose [8]. For example, occupational exposure to DEHP due to the usage of specific 
medical devices has been reported to be higher. Hemodialysis and kidney dialysis patients are 
exposed to DEHP at approximately 457 μg/kg body weight/day and global industry standards for 
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DEHP exposure can reach 700 μg/kg body weight/day [9] [10]. These levels of exposure are 
substantially higher than the EPA reference dose of 20 μg/kg body weight/day. 
Human exposure to DEHP has become a significant health concern as it is an endocrine-
disrupting chemical (EDC) and reproductive toxicant [4] [11-14]. DEHP and its associated 
metabolite mono-(2-ethylhexyl), MEHP, have been recognized as one of the most common 
environmental contaminants in human bodily fluids and tissues. Studies have reported that DEHP 
and MEHP are detectable in human bodily fluids, with almost 100% of tested human urine samples 
showing the presence of DEHP and MEHP. Detection of DEHP and MEHP were present in over 
95% of human blood samples [15]. Furthermore, detection of DEHP and MEHP were present in 
approximately 90–100% of amniotic fluid samples from second trimester fetuses [16] [17], as well 
as in breast milk [4] [18], umbilical cord blood [18] [19], and in ovarian follicular fluid [20]. 
The effects of prolonged exposure to DEHP or MEHP on female reproduction have 
recently become an active area of investigation. In studies by Hannon et al. [21-23] it was reported 
that DEHP exposure for 10 or 30-days in adult mice disrupted ovarian function, potentially causing 
infertility and premature ovarian failure. The results indicated that lower levels of DEHP, levels 
within the range of human exposure, altered estrous cyclicity, and accelerated primordial follicle 
recruitment by dysregulating phosphatidylinositol 3-kinase (PI3K) signaling. These alterations are 
present at higher doses but to a lesser degree. DEHP exposure for 30 days increased the percentage 
of time that the mice were in estrus. This study concluded that the decrease in primordial follicles 
accompanied by an increase in primary follicles after DEHP exposure accelerated follicle 
recruitment in vivo. Since females are born with a finite number of primordial follicles, 
acceleration of follicle depletion could eventually cause infertility [21-23]. These previous studies 
focused primarily on ovarian effects and did not investigate the effects of DEHP on the uterus. The 
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goal of the present study was to determine whether 30 days of exposure to DEHP in adult female 
mice, at doses representing the range of human exposure, would affect uterine morphology and 
function. We hypothesized that DEHP might have a direct effect on proliferation and 
differentiation of uterine cells, thus altering proliferation and typical morphological features in the 
uterus. 
2.2 Materials and Methods 
DEHP (99% purity) was purchased from Sigma-Aldrich (St. Louis, MO). Four stock 
solutions of DEHP were prepared, utilizing tocopherol-stripped corn oil (MP Biomedicals, Solon, 
OH) as the vehicle. The doses used were 20 μg/kg/day, 200 μg/kg/day, 20 mg/kg/day, and 
200 mg/kg/day.  Doses were prepared by using the stock concentrations of DEHP (0.0125, 0.125, 
12.5, and 125 mg/ml) for each respective dose. 
Doses were based on Hannon et al. [21-23] and selected to be in a range that is more 
environmentally and occupationally relevant than doses used in previous DEHP studies [24] [25] 
which dosed animals with up to 1000 mg/kg/day. The Agency for Toxic Substances and Disease 
Registry (ATSDRA) determined that the range of daily human exposure to DEHP is approximately 
3–30 μg/kg/day [26]. Furthermore, the Environmental Protection Agency (EPA) determined that 
the reference dose for DEHP is approximately 20 μg/kg/day. However, it is certainly possible that 
populations located in areas where high production or usage of DEHP occurs could be exposed to 
levels that exceed the reference dose, and we, therefore, included higher doses as well. 
Animals 
Cycling, adult female CD-1 mice at 39 days of age (reproductive age) were acquired from 
Charles River Laboratories (Wilmington, MA). The mice were housed at the University of Illinois 
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at Urbana-Champaign, Veterinary Medicine Animal Facility and were provided food and water ad 
libitum. Mice were housed in a controlled animal room environment, maintained at a temperature 
of 22 ± 1 °C, and on 12 h light-dark cycles. The Institutional Animal Use and Care Committee at 
the University of Illinois at Urbana-Champaign approved all procedures involving animal care, 
euthanasia, and tissue collection. 
 In vivo dosing regimen 
Oral dosing was conducted on mice at 39 days of age, with volumes that were determined 
and calculated daily according to the body weight of each mouse. Administration of the DEHP 
was by oral dosing, as this is the most common route of exposure to phthalates. The doses were 
given by inserting a pipet tip beyond the incisors towards the cheek pouch and delivering the 
specific dose of either vehicle or DEHP daily. The mice received either vehicle/control 
(tocopherol-stripped corn oil) or DEHP at 20 μg/kg/day, 200 μg/kg/day, 20 mg/kg/day, and 
200 mg/kg/day (n = 8/group) for 30 days. 
Hormone level analysis 
Hormone analysis was conducted to determine the effect of DEHP on ovarian steroid 
hormone levels. Euthanization of mice occurred after 30 days of treatment; blood was drawn 
immediately after euthanasia by heart puncture. Serum was collected and processed for enzyme-
linked immunosorbent assays (ELISA). Following the manufacturer's protocol using ELISA kits 
purchased from Diagnostics Research Group (Mountainside, NJ) measurements of levels of 
progesterone (P4) and 17β-estradiol were taken. The analytical sensitivity of each kit was 
0.1 ng/ml for progesterone and 9.71 pg/ml for estradiol. All samples were duplicated, all inter- and 
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intra-assay coefficients of variability were less than 10%. Mean values for each sample were used 
in this analysis. 
Morphological evaluation of the uterus 
Uterine tissues were aseptically collected and fixed in Dietrich’s fixative for at least 24 h 
for histological assessment of morphology, proliferation, and uterine measurements. The uteri 
were then transferred to 70% ethanol, embedded in paraffin wax (Tissue Tek VIP), and serially 
sectioned (5 μM) using a microtome (Microm 340). After that, the serial sections were mounted 
on Fisher Brand™ Super Frost microscope glass slides and allowed to cure for at least 24 h. To 
accurately quantitate morphological changes in the uterine sections, four representative sections 
that spanned the entire length (10 μm gap between sections to be mounted) of each uterine horn 
were mounted on glass slides and subjected to hematoxylin staining. Samples then underwent 
deparaffinization, followed by staining with hematoxylin and were cover-slipped. The use of the 
Hamamatsu Nanozoomer 2.0HT was used to scan samples. Images of samples were then assessed 
utilizing NDP.view.2 software, which allowed for all the tissue layers of each uterine section to be 
measured accurately. Quantitation was carried out by taking measurements at six random points 
for each tissue layer to eliminate bias and then averaging these six random measurements {Fig. 1). 
The measurements for each cross-section of the uterine samples were quantitated to determine the 
height of the luminal epithelium and thickness of myometrial layers. We also quantified the 
numbers of uterine glands and blood vessels. 
Assessment of cell proliferation 
To accurately quantitate cell proliferation in the uterine sections, four representative 
sections that spanned the entire length of each uterine horn were mounted on Fisher Brand™ Super 
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Frost microscope glass slides and subjected to immunohistochemical staining for proliferating cell 
nuclear antigen (PCNA) (Novus Biologicals., Littleton, CO). After deparaffinization and 
rehydration, uterine tissue samples underwent to heat-induced antigen retrieval with DAKO Target 
Retrieval Solution at 1:10 pH 9 (10x) (Dako Denmark A/S, Denmark, Part Number: S236784-2, 
Code: S2367) at 99.9° C for 20 min and allowed to cool to room temperature (RT). Samples were 
then inactivated by endogenous peroxidase activity with 3% H2O2/Methanol for 15mins. Samples 
were then rinsed in phosphate buffered saline-Tween-20 (PBST) and incubated in blocking 
solution consisting of 5% horse serum (Vectastain® ABC kit, Vector Laboratories, Inc. 
Burlingame, CA) at RT for 60 min. The tissue sections were then incubated with a primary anti-
PCNA-mouse antibody (Novus Biologicals., Littleton, CO) diluted in 1% BSA/PBST (1:500) and 
allowed to incubate overnight at 4° C. The negative control slides were incubated in a non-specific 
mouse IgG to confirm the specificity of the PCNA primary antibody. The following day, samples 
were rinsed with PBST and incubated with anti-mouse IgG secondary biotinylated antibody 
(Vectastain® ABC kit, Vector Laboratories, Inc. Burlingame, CA) in 1%BSA/PBST solution at a 
1:100 dilution at RT for one hour. Samples were then rinsed in PBST and incubated in ABC 
solution in 1%BSA/PBST (PBS: A: B = 50:1:1) for 30 min. All samples underwent exposure to 
chromogen 3’3-diaminobenzidine (DAB) (Vector Laboratories, Inc. Burlingame, CA) for 30 s. 
Slides were rinsed in tap water for 10 min to stop the DAB reaction. Counter-staining was with 
hematoxylin for 30 s followed by dehydration and then the sections were cover-slipped. 
The following day, the Hamamatsu Nanozoomer 2.0 HT was used to scan the samples. 
Images of samples were then assessed using NDP.view.2 software, allowing accurate 
quantification of proliferating cells within the luminal epithelium (LE) and stroma. Quantification 
of the LE proliferation; measured by the width of 5–10 cells within the luminal epithelium (LE) 
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and calculating the average width. The perimeter of the LE was measured using the NDP.view.2 
software. The total number of cells within the LE was calculated by taking the length of the entire 
LE and dividing this by the mean cell width to get the total number of cells. Proliferating cell 
counts were validated by manually counting the total number of cells within the LE of several 
samples and comparing this value with the value obtained using the mean width for a cell. The 
values obtained for these two methods were within 5% of each other. We then manually counted 
all positive cells within the uterine LE for each sample and used the following formula to calculate 
the percentage of proliferating cells in the LE: (Fig 1).  
In addition, analyses of  the average percentage of proliferating cells within the stroma was 
conducted from all eight animals within each treatment dosing group; 0, 20 μg/kg/day, 
200 μg/kg/day, 20 mg/kg/day, and 200 mg/kg/day. Ten random fields at 40 x magnification using 
NDP.view.2 software allowed accurate analyses for the number of proliferating cells within the 
stroma. The numbers of proliferating cells within the ten fields were averaged and divided by the 
area of the field to determine the number of proliferating cells per/1 mm2 in the stroma: Avg of 
proliferating cells ÷ field area = # proliferating cells/1 mm2 
Assessment of blood vessel number and morphology 
Immunohistochemistry was carried out for smooth muscle α-actin to determine whether 
uterine glands were invading into the myometrial layer (an indication of adenomyosis) of the 
uterus and for the detection of pericyte cells on blood vessels allowing for quantitation of the blood 
vessels. Four representative sections that spanned the entire length of each uterine horn were 
mounted on glass slides and subjected to immunohistochemical staining for smooth muscle α-actin 
(ACTA2) (Thermo Fisher., Rockford, IL) using the same protocol as described above with the 
primary antibody ACTA2 (Novus Biologicals., Littleton, CO) diluted at 1:200 in 1% BSA/PBST. 
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Stained slides were loaded into a Hamamatsu Nanozoomer 2.0 HT; images were scanned and then 
analyzed using NDP.view.2 software. The software allowed for accurate identification of smooth 
muscle myometrial layers and blood vessels within the endometrial stroma. Sections were 
quantitated at 40× magnification. The total numbers of blood vessels within the endometrial stroma 
were counted in each group (n = 8/treatment group) to determine the average number of blood 
vessels per treatment group. Lastly, the total numbers of dilated blood vessels were counted and 
divided by the total number of blood vessels within each treatment group to determine the 
percentage of dilated blood vessels within the endometrial stroma. 
Statistical analysis 
All data were analyzed using GraphPad Prism software 6 (GraphPad Prism, San Diego, 
CA). Data were expressed as means ± standard error of the means (SEM). Multiple comparisons 
conducted between normally distributed experimental groups were made using one-way analysis 
of variance (ANOVA) followed by Dunnett’s test comparison. Multiple comparisons between 
non-normally distributed groups were made using Kruskal Wallis tests when appropriate. This 
statistical significance was at p ≤ .05. 
2.3 Results 
The effect of DEHP on luminal epithelial and stromal cell proliferation 
We first assessed the effects of 30 days of exposure to DEHP on the proliferation of LE 
cells in the uteri of adult female mice using immunostaining for PCNA. Quantification of 
positively stained, proliferating cells in the LE was conducted using Nanozoomer software and is 
shown in (Fig. 2A–E) n = 8/treatment group). Results indicated that there was a significant 
decrease in the number of proliferating LE cells in both the 20 μg/kg/day DEHP (p < .039) and 
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200 μg/kg/day DEHP (p < .0058) treatment groups in comparison to the control group (Fig.2F 
n = 8/treatment group). We also assessed the numbers of proliferating cells within the endometrial 
stroma, to determine whether exposure to DEHP for 30 days caused alterations in stromal cell 
proliferation. Analysis determined that 30 days of exposure to DEHP caused a marked increase in 
cell proliferation of the stromal cells for the 200 μg/kg/day DEHP (p < .0010), 20 mg/kg/day 
DEHP (p < .0001) and 200 mg/kg/day DEHP (p < .0186) treatment groups in comparison to the 
control group (Fig. 2G n = 8/treatment group). There were virtually no PCNA positive cells in the 
uterine glands or the myometrial cells for any of the treatment groups. 
The effect of DEHP on number of endometrial glands 
Hematoxylin staining of samples enabled for the detection of uterine endometrial glands 
(GE) in uterine cross sections (Figure 3A–E n = 8/treatment group). Uteri of mice exposed to 
DEHP at 200 mg/kg/day (n = 8/treatment group) for 30 days showed a significant increase in the 
numbers of glands within the endometrial stroma compared to the control group (Figure 3F, 
n = 8/treatment group; P < .0021). Exposure to lower doses of DEHP for 30 days did not 
significantly affect the number of glands in the endometrium of the uterus. 
The effect of DEHP on blood vessels 
Immunohistochemistry for ACTA2 showed no evidence of invasion of endometrial glands 
(GE) into the inner myometrial layer in any of the treatment groups (Fig.4A–E, n = 8/treatment 
group). Immunostaining for ACTA2 also allowed observation of pericyte cells of blood vessels to 
quantitate blood vessels within the endometrial stroma for all treatment groups (Figure 4A–E 
n = 8/treatment group). There was no significant difference in the total number of blood vessels 
between the groups (Figure 4F, n = 8/treatment group). However, we observed the presence of 
40 
dilated blood vessels within the uterine cross-sections for some of the treatment groups and 
quantified these to determine if exposure to DEHP caused an increase in the percentage of dilated 
blood vessels within the endometrium. The results of this analysis determined that 30 days of 
exposure to DEHP caused an increase in the numbers of dilated blood vessels in the 200 μg/kg/day 
(p ≤ .0016), 20 mg/kg/day (p ≤ .0127) and 200 mg/kg/day (p ≤ .0087) treatment groups compared 
to controls (Figure 4G n = 8/treatment group). 
The effect of DEHP on myometrial morphology 
The effect of 30 days of exposure to DEHP assessment of morphological features of the 
outer longitudinal and inner circular myometrial layers of the uterus. Measurements of the 
thickness of the outer myometrial (O. Myo) layer at six random points within each uterine sample 
cross-section for four separate cross sections/sample and averaged the thickness (Figure 5A 
n = 8/treatment group). Statistical analysis indicated that there were no significant differences in 
the thickness between the control and DEHP exposed treatment groups (Figure 5B n = 8/treatment 
group). We also quantitated the thickness of the inner myometrial (I. Myo) layer using the same 
measurement methods (Figure 5C n = 8/treatment group). Again, there were no significant 
differences in the thickness of the DEHP-treated groups compared to the control group (Figure 
5D, n = 8/treatment group). 
The effect of DEHP on the morphology of the uterine epithelium 
The height of the luminal epithelial (LE) cell layer was measured at six random points on 
four separate cross-sections for each sample and averaged (Figure 6A n = 8/treatment group). We 
found no significant statistical differences between the control group and DEHP treated groups for 
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the height of the uterine epithelium and observed no multi-cellular layers/hyperplasia occurring in 
the groups exposed to DEHP (Figure 6B n = 8/treatment group). 
Effect of DEHP exposure on serum hormone levels (E2 and P4) 
 The effects of 30 days of exposure were assessed by Dr. Hannon to determine whether 
DEHP has an effect on serum hormone levels of E2 and P4 of adult female mice in estrus using 
ELISAs. After quantification, the results confirmed that there were no significant differences in 
the levels of E2 (Supplemental Data 2A n = 8/treatment group, p ≤ .05) or P4 (Supplemental Data 
2B n = 8/treatment group, p ≤ .05) between any of the treatment groups after 30 days of exposure 
to DEHP. 
2.4 Discussion 
The goal of this study was to evaluate the effects of adult exposure to the plasticizer DEHP 
for 30 days on the female reproductive tract, specifically on the uterus. The results of our study 
showed that exposure to DEHP for 30 days at environmentally relevant levels (20 μg/kg/DEHP 
day, 200 μg/kg/DEHP day) reduced the percentage of proliferating cells in the LE compared to the 
control group. Also, we determined that exposure to DEHP for 30 days caused a substantial 
increase in stromal cell proliferation at both environmental and occupational levels 
(200 μg/kg/DEHP day, 20 mg/kg/DEHP day, 200 mg/kg/DEHP day). Treatment with the highest 
concentration of DEHP (200 mg/kg/day) resulted in an increased number of uterine glands. 
Finally, our data also demonstrated that both environmentally and occupationally relevant doses 
of DEHP (200 μg/kg/DEHP day,20 mg/kg/DEHP day and 200 mg/kg/DEHP day) caused an 
increase in the numbers of dilated blood vessels within the endometrial stroma. These changes in 
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uterine morphology suggest that DEHP exposure alters the standard steroid hormone action in the 
uterus. 
Exposure to DEHP for 30 days in adult female mice did not cause any significant changes 
in serum levels of the steroid hormones E2 and P4 at estrus. Somasundora et al., [27] observed a 
decrease in mRNA of ERs (ERα) and an increase in P4 levels in the uterus after 30 days of 
exposure to DEHP in adult female rats. In vitro studies reported that DEHP at concertation ranging 
from 1 to 100 μg/ml caused a reduction of P4, testosterone, and estradiol production by cultured 
ovarian antral follicles [21-23]. Also, mice were observed to have a longer duration of estrus during 
their estrous cycles suggesting a pro-estrogenic effect of DEHP [21]. However, the effects of 
DEHP do not appear to be at the pituitary as there were no differences in either LH or FSH levels 
in mice treated with different doses of DEHP for 30 days [21] [23]. However, DEHP induces 
dysregulation of the pituitary-gonadal feedback and alters the reproductive performance of 
exposed animals [28]. These findings suggest that the marked effects of DEHP on uterine cell 
morphology and function that we observed in this study were more likely due to direct effects of 
DEHP on the uterus. 
Exposure to DEHP for 30 days significantly increased proliferation of endometrial stromal 
cells at the three highest doses tested (200 μg/kg/DEHP day, 20 mg/kg/DEHP day, 
200 mg/kg/DEHP day). In contrast, there was a decrease in the percentage of proliferating cells in 
the uterine LE (20 μg/kg/DEHP day and 200 μg/kg/DEHP day). These alterations in the typical 
pattern of endometrial cell proliferation are similar to changes reported for women on progestin-
only contraceptives [29-31]. Changes in the typical pattern of proliferation of cells within the 
uterus may indicate that prolonged DEHP exposure leads to disruption of the normal E2-P4 
responses in the uterus leading to an anti-estrogenic or pro-progestational effect. Studies have 
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shown that E2-dependent uterine epithelial cellular proliferation is controlled by stromal-mediated 
paracrine mediators, including genes such as Bmp8a Fgf10 and Hox10 [32-36]. These genes are 
upregulated in the epithelial, but down-regulated in stromal cells following E2 increases. It is 
possible that DEHP alters standard E2 functionality leading to a more progesterone-dominant 
environment that promotes stromal cell proliferation but diminishes epithelial cell proliferation. 
The myometrium showed few if any proliferating cells and there were no differences between any 
of the treatment groups. 
DEHP exposure for 30 days at the highest dose (200 mg/kg/day) significantly increased the 
number of uterine glands compared to the control group. During the menstrual/estrous cycle, E2 
is secreted from the follicles and prepares the uterus for receptivity. The proliferation of LE cells 
as they undergo proliferation involves budding of emerging glands from the luminal epithelium 
followed by extensive cell proliferation in these structures as they grow into the surrounding 
stroma, where the glands elongate and mature [37][38]. Although there was an increase in the 
number of glands in uteri from mice exposed to 200 mg/kg/day DEHP, there were few if any 
proliferating cells in the glandular epithelium. Suggesting that proliferation resulting in more 
glands may have occurred earlier during the exposure period and that by 30 days, proliferation was 
decreasing. Further studies assessing the effects of DEHP on the uterus after different periods of 
exposure are warranted. 
Immunostaining for smooth muscle α-actin allowed detailed observation of the blood 
vessels within the uterine stroma due to the positive staining of pericyte cells located around the 
vessels. [39][40]. Rouget first described pericyte cells [41], and subsequent studies have confirmed 
that these pericytes wrap around the endothelial cells of blood vessels [39][42-46]. Pericytes 
support endothelial cells by maintaining blood vessel and microvascular integrity [43]. They also 
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influence the functionality of blood vessels, including microvascular contractility and solute 
permeability [43]. We did not observe any breakage in the pericyte layers surrounding the 
abnormally dilated blood vessels, but it is possible that continued exposure to DEHP could 
ultimately lead to further loss in the structural integrity of the vessels. However, data showed that 
adult exposure to DEHP at 200 μg/kg/day, 20 mg/kg/day, and 200 mg/kg/day caused abnormal 
dilation of blood vessels in the endometrium. There was, however, no effect of DEHP treatment 
on the overall number of endometrial blood vessels between the treatment groups. Our data 
indicated that DEHP exposure led to a marked increase in the numbers of abnormally dilated blood 
vessels in the endometrial stroma, similar to in women exposed to progestin-only contraceptives. 
Studies have reported that prolonged exposure to contraceptive progestins and progesterone 
receptors modulators in women lead to abnormal dilation and thin-walled blood vessels in the 
endometrium [29-31]. Although we did not observe any signs of bleeding from the uterus or vagina 
in our mice, prolonged exposure to DEHP at both environmental and occupational levels could 
potentially contribute to the irregular bleeding common with such contraceptives [29-31]. These 
results, along with the observed reduction in epithelial cell proliferation, suggesting that extended 
DEHP exposure leads to a dominant progesterone environment in the uterus similar to that 
observed in women on oral contraceptives. 
DEHP exposure did not significantly affect the height of the uterine luminal epithelium 
(LE) for any of the treatment groups in our study. A decrease in the LE could contribute to failed 
embryo implantation and maintenance of implanted embryo. Studies have shown that the LE 
ultrastructure, LE cell surface components, lateral adherent junctions, gap junction channels, and 
subepithelial extracellular matrix (ECM) all change during the establishment of uterine receptivity 
[47][48]. Thus, any morphological alterations such as a reduction in the height of the LE could be 
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indicative of changes in these LE cell surface components and dysregulation of specific genes 
essential for preimplantation, implantation and maintenance of the embryo. A study by Li. et al., 
[25] reported that DEHP exposure inhibited the proper formation of pinopodes, which are 
membrane structures that protrude from the LE during the period of embryo receptivity. These 
structures are necessary for blastocyst attachment. Schmidt et al. [49] reported that F0 dams 
exposed to occupational levels of DEHP of 500 mg/kg/BW/day for eight weeks experienced a 
100% abortion rate. Furthermore, such findings of increased abortion rates of animals exposed to 
500 mg/kg/BW/day have been found in another study as well [28]. Such findings suggest that 
DEHP can potentially inhibit proper implantation of embryos through morphological and 
functional modifications of the LE. 
Due to the almost ubiquitous exposure to DEHP in the environment, there is a great interest 
in understanding how DEHP may impact reproductive function. Several studies are found in the 
literature, with the majority of these focused on male reproduction. These studies have utilized 
male mice and rats as models to understand the effects of DEHP on various reproductive endpoints. 
Investigators have reported that exposure to DEHP increases liver weight, reduces steroidogenic 
enzyme gene expression, anogenital distance (AGD), and leads to a reduction in numbers of sperm 
and sperm quality [28][50-57]. In a previous study [50], mice exposed to 1/6 LD50 had reduced 
epidydimal sperm numbers by four weeks. However, the morphology of the sperm did not differ 
from the control in 12 weeks following treatment. Also, DEHP did not increase the number of 
peripheral blood micronuclei of the testes. Other studies demonstrated that immature male mice 
treated daily with DEHP from postnatal day one until 60 days of age had a decrease in both quality 
and quantity of spermatozoa [50]. 
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Furthermore, exposure to DEHP caused down-regulation in several different genes 
indicating that DEHP induces pathological alterations in the testes [52]. Another study observed 
that DEHP depletes zinc in the testes as a secondary effect. However, apoptosis and necrosis of 
the testes occurred before this, along with extremely reduced numbers of spermatozoa [51]. 
Unfortunately, DEHP studies focusing on the effects of DEHP in female reproduction are sparse 
and have primarily utilized rodent models. Female mice exposed to DEHP as adults have been 
reported to experience increased body weight, increased post-implantation fetal losses, increased 
ovarian weight, altered follicullogenesis, and oocyte development, and disrupted estrous cyclicity 
[28][49][54]; Hannon et al. [21-23][55]. Exposure to DEHP has been determined to influence the 
duration of the female estrous cycle, suggesting that DEHP may alter normal reproductive 
function. Also, exposure to DEHP caused a 40% increase in ovarian weight, a reduction in the 
numbers of oocytes that reached the MII stage, lower expression of steroidogenesis enzymes and 
gonadotropin-receptors in the gonads and up-regulation of gonadotropin subunit genes in the 
pituitary [28]. All these studies suggest that exposure to DEHP may affect normal reproduction 
function at a variety of target tissues. Few if any studies have investigated the effects of extended 
adult exposure to DEHP on the uterus. However, the results in from this current study show that 
there is a strong correlation between DEHP exposure and alterations of the adult uterus further 









Figure. 2.1. Cross-section of uterus assessed and quantitated utilizing Nanozoomer software. Six 
random measurements for each respective layer; Outer Myometrium (O.Myo), Inner Myometrium 
(I.Myo) and Luminal Epithelium (LE) height/thickness, were conducted to ensure unbiased 
measurements. The total number of glands (GE) were also quantitated in each uterine section as 














Figure. 2.2. The effect of DEHP on the luminal epithelium (LE) and stroma cellular proliferation. 
(A–E) Representative cross-section of the uterus; arrows points to positive stained cells-brown. 
PCNA allowed for the identification of positive (+) cells in LE and stroma. (F) Percentage of cells 
undergoing cellular proliferation within each treatment group. One-way ANOVA Multiple 
Comparison statistical analysis. Asterisks (*) represent a significant difference from vehicle 
control (p ≤ 0.05). (G) The number of stroma cells undergoing cellular proliferation Treatment 
group 20 μg/kg/day DEHP (p ≤ 0.0393) and 200 μg/kg/day DEHP (p ≤ 0.0058). Asterisks (*) 
represent a significant difference from vehicle control (p ≤ 0.05). 200 μg/kg/day DEHP 
(p ≤ 0.0010), 20 mg/kg/day DEHP (p ≤ 0.0001) and 200 mg/kg/day DEHP (p ≤ 0.0186) treatment 
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Figure. 2.3. The effect of DEHP on endometrial glands. (A–E) Representative cross-section of the 
uterus; arrows point to endometrial glands (GE). (F) The average number of glands within each 
treatment group. One-way ANOVA Multiple Comparison statistical analysis. Asterisks (*) 
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Figure. 2.4. The effect of DEHP on endometrial blood vessels; α-Smooth Muscle stained of 
pericyte cells in blood vessels. (A-E) treatment groups exposed to different doses of DEHP; arrows 
indicate blood vessels. (F) Statistical evaluation for the total number of blood vessels in the stroma. 
(G) Statistical evaluation for the percentage of dilated blood vessels in the stroma. One-way 
ANOVA Multiple Comparison statistical analysis. Asterisks (*) represent a significant difference 
from vehicle control (p ≤ 0.05). Asterisks (*) represent a significant difference from vehicle control 




















































Figure. 2.5. The effect of DEHP on myometrial layer thickness in adult CD-1 mice. (A) 
Representative cross-section of the uterus showing measurements of the outer myometrial layer. 
(B) The graph shows the average height/thickness of outer myometrium within each treatment 
group. (C) Representative cross-section of the uterus showing measurements of the inner 
myometrial layer. (D) The graph shows the average height/thickness of inner myometrium within 
each treatment group. The x-axis represents treatment groups; the y-axis represents the thickness 
of myometrium in μm. One-way ANOVA Multiple Comparison statistical analysis. There was no 
significant difference from vehicle control (p ≤ 0.05). 
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Figure. 2.6. The effect of DEHP on the uterine luminal epithelium (L.E.) (A) Representative cross-
section of the uterus with measurements of the LE (B) Average height/thickness of myometrium 
within each treatment group. The x-axis represents treatment groups; the y-axis represents 
thickness/height in μm. One-way ANOVA Multiple Comparison statistical analysis. There was no 









Supplementary Figure. 2.1. The effect of DEHP on serum hormone levels of E2 and P4. (A) Levels 
of E2 measured in serum; (B) Levels of P4 measured in serum. Mean values for each set of samples 
were determined. Differences were assessed using one-way ANOVA with Multiple Comparisons. 
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Chapter 3: The Effects Of A Phthalate Mixture On Preimplantation Embryo Development 
And Function 
3.1 Introduction 
Globally, reproductive failure is of significant concern among many women of 
reproductive age (14-55 years of age), globally [1, 2, 3]. Although there are several factors which 
cause reproductive failure, identifying the probable causes of reproductive failure is of significant 
concern and is continuously being investigated [4, 5, 6]. Several factors may contribute to 
reproductive failures such as, but not limited to, genetics, diet, stress, sexually transmitted 
infections (STIs), hormone imbalance, environment, and drug abuse. Among all these factors, one 
environmental aspect that is associated with reproductive failure is exposure to endocrine 
disrupting chemicals (EDCs), as humans are exposed to them daily. EDCs are chemical 
compounds that can interact with the endocrine systems of humans and animals by influencing 
hormone metabolism [6, 7, 8, 9, 10]. EDCs can disrupt synthesis, secretion, transport, binding 
action or elimination of hormones, including those that are responsible for behavior and fertility, 
resulting in severe consequences for the reproductive and endocrine systems [10, 11]. 
One of the more widely utilized EDCs are phthalates. Phthalates are a family of structurally 
related chemicals that are used as plasticizers and additives in a variety of products such as 
polyvinyl chloride (PVC), cosmetics, adhesives, flooring, and medical supplies [12,13,14]. 
Although phthalates are useful and have low production cost, they readily leach from products into 
the environment and can enter biological tissues. Due to high usage and human exposure, 
phthalates have become a significant health concern because they are known EDCs and 
reproductive toxicants. One of the more widely utilized phthalates di-(2-ethylhexyl) phthalate 
(DEHP) has been shown to have adverse reproductive effects [15, 16, 17, 18, 19]. 
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Studies have documented that phthalates such as DEHP can alter and impair reproductive 
homeostasis in both males and females [20, 21]. Although such findings are critical to further 
understand health effects due to exposure to phthalates, many studies routinely used a single 
phthalate at extremely high doses, which is not environmentally or occupationally relevant-often 
over 100 times higher than human daily exposure levels which are not environmentally or 
occupationally relevant [22]. Furthermore, studies have shown that humans and animals are 
exposed to a variety of phthalates daily. Studies that have investigated phthalate mixtures have not 
used representative mixtures or doses based on actual phthalates present in humans [23]. Given 
the pervasive nature of phthalates and daily human exposure to a variety of different phthalates, it 
is imperative to investigate the effects of relevant phthalates mixtures. Limited data exist on the 
effects of EDC exposure on preimplantation embryo developments. Therefore, it is critical to 
investigate the potential effects of phthalate exposure on preimplantation embryo development.  
Preimplantation embryo development is the period before embryos implant into the uterus. 
During this phase of development, the zygote (fertilized one-cell embryo) will undergo several 
rounds of cleavage to transition into a hatching blastocyst, which is capable of implanting into the 
uterus and developing into a viable fetus. Preimplantation embryos undergo an array of complex 
morphological changes controlled by genetic regulatory networks [24]. These genetic regulatory 
networks are comprised of many genes (depending on the species) which are activated and 
degraded during certain stages of development [24, 25, 26]. Of these genes, several are critical for 
cell differentiation into the two cell lineages: 1) trophectoderm (TE) that will establish the placenta 
and 2) inner cell mass (ICM) that will become the fetus. Cell lineage formation occurs by 
differential expression of transcription factors such as octamer-binding transcription factor 4 (Oct-
69 
4), caudal type homeobox 2 (Cdx-2) and E-cadherin. These genes play vital roles in the 
development of the ICM and TE [25,27]. 
Oct-4 is a key component of the pluripotency regulatory network, and its reciprocal 
interaction with Cdx-2 has been shown to be a determinant of either the self-renewal of embryonic 
stem cells (ESCs) or their differentiation into trophoblast [27], thus Oct-4 considered the master 
regulator of pluripotency [27]. Oct-4 is initially present in the oocyte and, like many other maternal 
transcripts its expression declines upon the first cleavage, then reappears at the late 2-cell or 4-cell 
stage (depending on species) and is expressed in the blastomeres of the embryo. The expression of 
Oct-4 is restricted to pluripotent and totipotent cells, and its primary function is to regulate 
embryonic stem (ES) cell fate, through the promotion of constant self-renewal and interaction with 
other genes such as SOX-2. Alteration of Oct-4 has been shown to decrease the viability of embryo 
survival [28, 29, 30]  
Cdx-2 is expressed during the morula stage when the cell types begin to differentiate [31]. 
The increased level of Cdx-2 represses Oct-4 within perimeter blastomere cells, thus resulting in 
Cdx-2 dominance in those cells. Embryos with zygotic deletion of Cdx-2 usually develop until the 
late blastocyst stage, however they are unable to implant into the uterus. Thus, leading to the 
conclusion that Cdx-2 is involved only in the maintenance of the TE lineage [31,32, 33]. 
E-cadherin is a single-pass transmembrane glycoprotein containing five extracellular 
repeats that mediate Ca2+-dependent homophilic interaction with opposing molecules on 
neighboring cells [33]. The five Ca2+ repeats extend out and interact with the neighboring cell(s), 
which also have the same structures present, thus allowing adhesion between the cells to occur. 
The presences of E-cadherin play a critical role in the adhesion of blastomeres initiating the 
compaction of embryos at the 8-cell stage. 
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Alteration of these genes during early development, can cause embryos to become sub-
optimal for implantation or non-viable depending on the severity of dysregulation [27,34]. 
Therefore, disturbances in gene expression during development can result in reduced development, 
pregnancy outcomes, or health complications later in life for humans as well as animals. Other 
factors that are associated with decreased viability are micronucleation and fragmentation.  
Micronuclei are small nuclear fragments that form when a chromosome remains separate 
from the core chromosome once the nuclear envelope reorganizes. This phenomenon is the results 
of the mis-attachment of chromosomes due to lagging during mitosis, which, correlates with 
chromosomally unstable cells and result in the formation of micronuclei. The presences of 
micronucleation is speculated to occur due to genetic aberration from either maternal or paternal 
DNA, or due to exposure to chemicals causing genotoxicity [35]. Micronucleation can result in; 
apoptosis of the blastomere(s), aneuploidy (misshapen or abnormal number of chromosomes) 
increased fragmentation, cellular arrest, and a decrease in blastocyst development or reduced 
implantation.   
Fragmentation is a phenomenon that occurs when portions of cytoplasm are enclosed by 
the cell membrane during cell division that do not contain DNA. Fragmentation is associated with 
irregular cell division of the blastomeres cell(s) of the embryo leading to an abnormal shape and 
increases the risk of apoptosis in adjacent cells leading to disruption of blastulation [36, 37, 38, 
39, 40]. The consequent loss of cytoplasmic volume causing a reduction in implantation potential 
[39, 40, 41]. Therefore, fragmentation is an established marker of embryo viability and 
implantation. 
Studies that have investigated the effects of exposure to a single phthalate or other EDCs 
have shown a reduction of preimplantation embryo development. Chu et al., 2013 [29] reported 
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that preimplantation embryos exposed to 10-3 M Mono-(2-Ethylhexyl) phthalate (MEHP) induced 
2-cell embryo block and decreased heat shock cognate 70 (Hsc70), murine endogenous retrovirus 
(MuERV‐L) mRNA level, and Sox2 protein levels. In addition, this study showed that exposure 
markedly increased heat shock protein 70 (Hsp70.1), eukaryotic translation initiation factor-1A 
(eIF‐1A), zinc finger and SCAN domain containing 4 (Zscan4) mRNA level, and Oct4 protein 
level at the 2‐cell and 4‐cell stage [29]. Another study suggested that prenatal exposure to 100 
mg/kg/day of bisphenol A (BPA) affects blastocyst transport, overall development of embryos and 
the establishment of uterine receptivity for hatched embryos on day 5 [42]. These studies are 
essential to further understand the effects of EDCs on preimplantation embryos and exposure 
correlation to reproductive failures in women. However, limited studies have observed the effects 
of relevant phthalate mixtures on preimplantation embryo development. Therefore, it is imperative 
to investigate development, genetic function, and mechanism(s) of preimplantation embryos 
exposed to a relevant phthalate mixture.  
 Zhou et al. [43,44] developed a phthalate mixture consisting of 35% diethyl 
phthalate (DEP), 21% di (2-ethylhexyl) phthalate (DEHP), 15% di-n-butyl phthalate (DBP), 15% 
di-isononyl phthalate (DiNP), 8% di-isobutyl phthalate (DiBP) and, 5% benzyl butyl phthalate 
(BBzP). This phthalate mixture is based on the urinary phthalate metabolite levels detected in 
pregnant women in Illinois. These studies established a relevant phthalate mixture which is 
relevant to human exposure [45]. These studies demonstrated that female mice born to phthalate 
mixture exposed dams had disrupted estrous cyclicity, reduced fertility-related indices, and caused 
breeding complications compared to female mice born to vehicle control exposed dams [43,44].   
Overall these studies have shown that exposure to EDCs reduces successful pregnancies 
and implantation, increases cellular arrest, and disturb gene expression [22, 29, 42, 43, 44]. 
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However, none of these studies primarily observed the effects of preimplantation embryos exposed 
to a relevant phthalate mixture. Given the findings of these studies, it is extremely plausible that 
exposure to a relevant phthalate mixture will alter or interfere with the development of 
preimplantation embryos. Thus, the objective of this study was to determine whether exposure to 
a relevant phthalate mixture affects the development of preimplantation embryos.   
3.2 Materials and Methods 
Chemicals  
To properly conduct this experiment, DEP, DEHP, DBP, DiNP, DiBP, and BBzP (99% 
purity) were purchased from Sigma-Aldrich (St. Louis, MO). A pure phthalate mixture was made 
by calculating and combining the appropriate amount of each phthalate according to the following 
percentages 35% DEP, 21% DEHP, 15% DBP, 15% DiNP, 8% DiBP, and 5% BBzP. The 
percentages were derived from levels of phthalate metabolites measured in urine samples from 
pregnant women in Illinois (data from the iKids study). Then, the phthalate mixture was mixed 
thoroughly before dilution in dimethyl sulfoxide (DMSO) which was used as a vehicle control.  
The doses used for this study were control (LifeGolbal LGGG-100 culture medium), 
DMSO 0.075%, 0.001 µg/mL, 0.01 µg/mL, 0.1 µg/mL, and 1µg/mL. Phthalate dose percentages 
are based on the study design of Zhou et al. [43,44] and selected to be in a range that is more 
environmentally and occupationally relevant than doses used in previous single or mixture studies 
which cultured oocytes or embryos with up to 1000mg/kg/day. According to several global safety 
organization such as the Agency for Toxic Substances and Disease Registry (ATSDRA), 
Environmental Protection Agency (EPA), Center of Disease Control (CDC) and European Food 
Safety Authority (EFSA) the range of daily human exposure to each of the individual phthalates 
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are the following; DEP (0.07–90μg/kg/day), DBP (0.0058-4 ng/kg/day), BBzP (2-80μg/kg/day), 
DiBP (0.5-170 μg/kg/day), DiNP (1–10 μg/kg/day) and DEHP is approximately 3-30 µg/kg/day. 
Therefore, dose ranges were selected to mimic relevant levels observed in reproductive fluids [45, 
46, 47]. 
Phthalate mixture pH analysis 
 To determine whether exposure to a relevant phthalate mixture alters pH of culture media 
and contributes to embryo developmental failure, a total of 2 mL of the appropriate phthalate 
mixture were added to individual Falcon 14mL tubes (Fisher Scientific) containing either control, 
vehicle control or 0.001 µg/ml, 0.01 µg/ml, 0.1 µg/ml or 1 µg/ml and covered with a layer of 500 
µl of mineral oil. The 14 mL tubes were placed in a Thermo Fisher 8000 WJ CO2 incubator at 
37˚C, 5.0% CO2 and relative humidity (RH) of 75% and incubated for 24 hours. After incubation, 
the pH of each tube was documented using a Corning pH meter 430 probe. This same protocol 
was conducted for 120 hours to determine whether the phthalate mixture altered the pH on the 
final day of culture. 
Preparation of culture dishes and handling medium 
  Embryo culture and wash dishes were made in the following way. Precisely 1 mL of 
LifeGolbal LGGG-100 culture medium was added to autoclaved 3 mL glass tubes. After that, 
approximately 0.75 µl of the appropriate concentrations (DMSO (0.075%), 0.001 µg/mL, 0.01 
µg/mL, 0.1 µg/mL, or 1µg/mL) were added to the tube and thoroughly mixed. Individual Falcon 
35 mm center-well dish (wash dishes) had 500 µl of the appropriate mixture added to the center 
and were covered with equal amounts of mineral oil. To ensure that there was no cross-
contamination of the different treatment groups, individual Falcon 35 mm culture dishes were 
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established for each treatment group. Each dish had 5-6 droplets with a volume of 20 µl and 
covered with 9 mL of mineral oil. Handling medium was made adding by adding 9.5 mL optimized 
(3-(N-morpholino) propanesulfonic acid) (OMOPS) into a Falcon 14 mL tube. Handling medium 
was supplemented with 5% fetal bovine serum (FBS). Dishes (culture and washes) and handling 
medium were placed in a Thermo Fisher 8000 WJ CO2 incubator at 37˚C, 5.0% CO2 and 75% RH 
cultures were incubated overnight.  
 Animals  
Cycling, adult female CD-1 mice at 6-8 weeks of age (reproductive age) were acquired 
from Charles River Laboratories (Wilmington, MA). Adult male B6D2F1 at 3-12 months of age 
(reproductive age) were acquired from Charles River Laboratories (Wilmington, MA). The mice 
were housed at the University of Illinois at Urbana-Champaign, Animal Facility and were provided 
food and water ad libitum. Mice were housed in a controlled animal room environment, maintained 
at a temperature of 22 ± 1 °C, and on 12-hour light-dark cycles. The Institutional Animal Use and 
Care Committee at the University of Illinois at Urbana-Champaign approved all procedures 
involving animal care, euthanasia, and tissue collection.               
Mating and Collection 
CD1 female mice at 39 days of age were injected intraperitoneally (IP) with 6 IU (120µl) 
of pregnant mare serum gonadotropin (PMSG) at 3:30-4:00 pm.  Approximately 45-46 hours later, 
the mice were IP injected in the same location with 6 IU (120µl) of human chorionic gonadotropin 
(hCG) at 1:00 pm. Females were placed in a cage with fertility proven B6D2F1B males (1:1) 
immediately after hCG injection and allowed to mate overnight. The following morning, females 
were checked for a vaginal plug at 8-8:50 am. Females with plugs were removed and transferred 
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to an empty cage. Females were sacrificed 10:00 am (19hrs after mating), and ovaries oviducts, 
and uteri were placed into OMOPS handling medium supplemented with 5% fetal bovine serum 
(FBS).  
Under an Olympus SZX12 dissecting scope, contents were poured into a Falcon 35-mm 
dish. The ampulla of all uterine horns were punctured using a 25 G needle, releasing zygotes/one 
cell embryos into OMOPS holding media where all of the embryos were pooled. Embryos were 
collected and placed in a Falcon center-well dish containing 500 µl of OMOPS. If necessary, 25µl 
of hyaluronidase (375 U/mL) was added to the center-well dish to facilitate cumulus cell removal. 
Embryos were placed in hyaluronidase solution for 30 seconds and transferred to a new center-
well dish containing OMOPS to stop the reaction. Embryos were repeatedly aspirated through 
progressively smaller pipettes until all cumulus cells were removed and washed thoroughly in 
OMOPS and counted. Only high quality (fertilized, polar bodies, nuclei and intact zona pellucida) 
embryos were selected for culture. Quality embryos underwent a final wash in the respective 
treatment groups (control, DMSO, 0.001 µg/mL, 0.01 µg/mL, 0.1 µg/mL, or 1µg/mL) before being 
placed in final culture. A total of 10-18 embryos in replicates of 6, were used for each treatment 
group depending on the total number of female mice used and the quality of zygotes. 
Approximately ten embryos were placed into a 20µl droplet. Culture dishes were then placed in 
the incubator at 37˚C, 5% CO2, and 75% RH.  
Observation of embryo development   
 To observe embryo development, critical time points were established based on previous 
work by several different researchers [48]. Embryos were cultured from the zygote stage until the 
hatched blastocyst stage, approximately 120hrs total. Embryos were observed at the following 
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stages: 2-cell (46hrs post-mating), 8-cell (68hrs), morula (75hrs), blastocyst (96 hrs) and hatched 
blastocyst (120 hrs). During observation of development, the presence of fragmentation was 
documented as well. Developmental stages were observed utilizing an Olympus SZX12 dissecting 
microscope with a low light setting. Real-time images were obtained using a Zeiss Axio Vert.A1 
microscope at 20x magnification with a lower light setting. Total time of observation of embryo 
development at every stage was under one minute. A pervious study documented that increased 
time outside of the incubator and exposure to increased light would reduce the viability of embryo 
development [49]. 
Fixing of embryos and Immunofluorescence Staining 
Embryos were collected at the 4-cell (n=10/per treatment group), 8-cell (n=5 per/treatment 
group), blastocyst (n=5/per treatment group), and hatched blastocyst stage (n=10 per/treatment 
group). Embryos were fixed in 4% paraformaldehyde for 20 minutes and then washed in 400µl of 
washing buffer (containing 1x PBS, Triton X-100 and polyvinylpyrrolidone) three times for 10 
minutes, followed by incubation in 400µl permeabilization buffer (containing 1x PBS, Triton X-
100 and polyvinylpyrrolidone) for 30 minutes. Embryos were then blocked in 450 µl of blocking 
buffer with either 50 µl of normal donkey serum (Jackson Immuno Research) per well (ICM & 
TE) or 50 µl of normal horse serum (Vector Laboratories) per well (E-cadherin) for 2 hours 
followed by a wash for 25 minutes in washing buffer. The primary antibodies that were used to 
observe the different cell lineages were anti-Oct-4 rabbit mAB (Cell Signaling-D6C8T) (1:800) 
for ICM, Anti-Cdx2 mouse monoclonal antibody (Biogenex MU392A-100) (1:300) for the 
observation of the TE and cell adhesion was observed by anti-E-cadherin goat polyclonal (R&D 
Systems) (1:100). Oct-4 and Cdx-2 were conducted at the same time with 125 µl of each antibody 
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solution per well (total 250 µl/well). E-cadherin staining was done separately with 250 µl per well. 
Embryos were transferred to Ag six-wells dishes and incubated overnight at 4˚C.  
The following day, embryos were washed three times in wash buffer for 10 minutes, then 
incubated for 2 hours in secondary antibodies cyanine 3 (CY3) donkey anti-rabbit 555nm (Jackson 
Immuno Research 711-165-152) (1:500), cyanine 5 (CY5) donkey anti-mouse 690 nm (Jackson 
Immuno Research 715-175-151) (1:400) or Alexa Fluor 488 (Jackson Immuno Research 715-545-
150) (1:100). Embryos were washed two times for 20 minutes in antibody buffer followed by a 1-
hour wash in washing buffer. Embryos then were incubated in DAPI (Vectastain Laboratory) for 
30 minutes. After that, 80µl oil was added to a 35mm glass bottom dish with 14mm bottom well 
(Cellvis) and a maximum of 20µl of DAPI containing embryos. Afterward, a 22 x 22 mm high 
precision micro coverslip (Carl Zeiss™ Deckgläser) were placed over the DAPI droplet, and 
embryos were incubated overnight at 4˚C.  
Cell Count and Immunofluorescences Quantitation 
All embryos were scanned at 20x/0.8 magnification using the Zeiss LSM 880 Airyscan 
microscope. The channel detection wavelength was set to 415-481nm (DAPI), 557-630 (CY3), 
and 630-758 (CY5) or 488-588 (Alexa Fluor 488) for immunofluorescence. Blastocyst cell count 
analysis was performed using 9.1 Imaris software (Oxford Instruments). Z-stack images of the 
blastocyst were counted by slicing through the entire images and counting the total number of ICM 
and TE cells.   
Immunofluorescence of Oct-4 and E-cadherin intensity quantitation was conducted by 
obtaining the raw data Carl Zeiss Image (czi) images of each embryo and measuring fluorescence 
intensity using Blue Zen 2 software. To properly analyze the entire embryo, the measurement 
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distance between planes were 2.38 µm (4-cell embryos) or 5.38 µm (8-cell embryo and blastocyst) 
respectively. The measurement plane distances were chosen due to the stage of development, size, 
and the overall number of total slices of the embryos. Four random points were selected for each 
embryo at later stages of development (8-cell and blastocyst stage), and the total numbers of 
intensity peaks were measured at each distance then the total average intensity was output.  
Statistical analysis 
All data were analyzed using GraphPad Prism software 7 (GraphPad Prism, San Diego, 
CA). Data were expressed as means ± standard error of the means (SEM). Statistical analysis 
conducted for preimplantation development was done using multiple comparisons analysis, were 
conducted between normally distributed experimental groups using one-way analysis of variance 
(ANOVA) followed by Dunnett’s test comparison. Multiple comparisons between non-normally 
distributed groups were made using Kruskal Wallis tests when appropriate. Also, Chi-square and 
Fisher Exact used for the presence of micronucleation. Statistical significance assigned at p ≤ 0.05. 
3.3 Results 
The effects of phthalate mixture on culture pH 
  The pH assessments were conducted to determine whether the phthalate mixture 
concentrations affected the pH of the culture medium, thus altering preimplantation embryo 
development. The results indicate that there were no significant differences in pH between the 




The effects of phthalate mixture on preimplantation development 
 These assessments were conducted to determine the effects of a relevant phthalate mixture 
on preimplantation embryo development. The results indicate that the phthalate mixture 
significantly decreased preimplantation embryo development at different stages compared to 
control. At the 2-cell stage, the phthalate mixture did not significantly affect embryo development 
compared to control [Figure 1A-C]. Exposure to the phthalate mixture at 0.01µg/mL,0.1µg/mL 
and 1µg/mL, significantly decreased the percentage of embryos that progressed to the 8-cell stage 
compared to the control (0.01µg/mL: 46.5% ±10.64, n=71; 0.1µg/mL: 41.12% +9.81, n=102; 
1µg/mL: 32.92%+11.11, n=95; control: 79.57%+5.31, n=74) [Figure 1D-F]. Many of the embryos 
at the 8-cell stage were observed arrested in the 4-cell stage. In fact embryos in 0.1µg/mL and 
1µg/mL treatment groups had a significant increase in the total number of embryos that were 
arrested in the 4-cell stage compared to the control (0.1µg/mL:  46.63%+3.75, n=102; 1µg/mL: 
40.79+9.25, n=95; control: 6.86%+3.78, n=74) [Table 1] [Figure 1G].   
Exposure to the phthalate mixture at 0.01µg/mL,0.1µg/mL and 1µg/mL, but not               
0.001 µg/mL significantly decreased the percentage of embryos which cleaved/divided to the 
morula stage compared to the control (0.01µg/mL: 55.28% + 9.00, n=71; 0.1µg/mL: 41.21% + 
7.82, n=102; 1µg/mL: 49.27% + 8.59, n=95; control: 90.06% + 1.25, n=74) [Figure 1H-J]. At the 
blastocyst stage, the mixture at 0.01µg/mL, 0.1µg/mL, and 1µg/mL, but not 0.001µg/mL 
significantly decrease the percentage of embryos which cleaved to the blastocyst stage compared 
to the control group, (0.01µg/mL: 56.67% + 7.14, n=71 ; 0.1µg/mL: 32.11% + 6.69 , n=102; 
1µg/mL: 39.45% + 10.40 , n=95; control: 82.60% + 2.83, n=74), [Figure 1K-M]. Lastly, the 
mixture at 0.01µg/mL, 0.1µg/mL, and 1µg/mL significantly decreased the percent of embryos 
which developed to the hatched blastocyst stage compared to the control (0.01µg/mL: 51.67% + 
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5.42, n=71; 0.1µg/mL: 40.1% + 9.16, n=102; 1µg/mL: 33.56.45% + 9.93, n=95; control: 80.07% 
+ 2.62, n=74), [Figure. 1N-P]. Overall exposure to higher levels to the phthalate mixture are shown 
to have significant effects on embryo development.   
The effects of phthalate mixture on preimplantation fragmentation 
During observation of preimplantation embryo development, the presence of fragmentation 
was documented using Zeiss Axio Vert.A1 microscope. Embryos were observed from the 2-cell 
to 8-cell stage to determine the total percentage of embryos within each treatment group that 
displayed fragmentation [Figure 2A-C]. The results of this analysis determined the phthalate 
mixture significantly increased the percentage of fragmentation in treatment group ((0.1µg/mL: 
25.38% + 6.143, n=102 (p<0.0061) and 1µg/mL: 26.20% + 7.00, n= 95 (p<0.0043)) compared to 
the control: 2.94% + 1.912, n=74 and DMSO: 5.08% + 2.72, n=93 treatment group [Figure.2D]. 
The results also showed that there was an increase in the number of embryos with a  degree of 
fragmentation  at >20% [Figure 2E]. 
Phthalate mixture interferes with Oct-4 expression at the 4-cell stage 
 The assessment was conducted to determine whether a relevant phthalate mixture affects        
Oct-4 expression [Figure 3 A-D]. This assessment showed that the phthalate mixture significantly 
increased the expression of Oct-4 in treatment group 1µg/mL compared to the vehicle control 
(DMSO). These data were determined by the increase of relative fluorescence units (RFU) 
intensity of Oct-4 group (1µg/mL: 38.5 RFU, n=5; DMSO: 23.26 RFU, n=5) [Figure. 3E]. 
However, the mixture at 0.001µg/mL, 0.01µg/mL, and 0.1µg/mL did not cause significant 
differences in intensity compared to vehicle control. 
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Phthalate mixture affects E-cadherin levels at the 8-cell stage 
The assessment was conducted to determine whether a relevant phthalate mixture affects E-
cadherin expression. The results indicated the preimplantation embryos in phthalate mixture 
treatment groups 0.01µg/mL 0.1µg/mL and 1µg/mL had a significant decrease in E-cadherin RFU 
compared to the control (0.01µg/mL: 29.74 RFU, n=5; 0.1µg/mL: 41.41 RFU, n=5; 1µg/mL: 34.82 
RFU, n=5; control: 67.70 RFU, n=5) [Figure. 4A-E]. Upon observation, the mixture also caused a 
small degree of incomplete/patches between compacted blastomeres compared to control.  
The effects of a relevant phthalate mixture on E-cadherin level in blastocyst  
The assessment was conducted to determine whether a relevant phthalate mixture affects E-
cadherin expression [Figure. 5A-B]. The mixture did not affect E-cadherin levels compared to the 
control. 
The effects of phthalate mixture on blastocyst cell population 
The phthalate mixture did not cause significant statistical differences in the number of cells 
present in the ICM, TE, and total number of cells or the ratio between ICM: TE compared to the 
control group of embryos that were cultured in the respective mixture for 120 hrs [Table 2] [Figure 
6A-D].  
Exposure to phthalate mixtures increases risk of micronucleation of preimplantation 
embryos 
The assessment to determine whether exposure to a relevant phthalate mixture increased 
the presences of micronucleation in preimplantation embryos. The results of this study indicated 
that the mixture at 1µg/mL significantly increase of the percentage of embryos which had 
82 
micronucleation in at least one blastomere, compared to the control group (1µg/mL: 43%, n=7; 
control: 0%, n=10) [Figure 7A-F]. However, at the 8-cell and blastocyst stage, the mixture did not 




The goal of this study was to evaluate the effects of preimplantation embryos exposed to a 
relevant phthalate mixture during development from the zygote to hatched blastocyst. The result 
of this study demonstrated that exposure to a relevant phthalate mixture (0.01 µg/mL, 0.1 µg/mL, 
1 µg/mL) reduced the percentage of the overall development of preimplantation embryos 
compared to the control and vehicle control treatment group. In addition, we determined that 
exposure to a relevant phthalate mixture caused a substantial increase in fragmentation (0.1 µg/mL 
and 1 µg/mL) compared to the control and vehicle control treatment group. Of the fragmented 
embryos, majority of the embryo had a high degree of fragmentation within those same treatment 
groups (0.1 µg/mL and 1 µg/mL). The highest concentration of the phthalate mixture (1 µg/mL) 
also caused an increase in Oct-4 expression at the 4-cell stage. Further, exposure to the relevant 
phthalate mixture (0.01 µg/mL, 0.1 µg/mL, 1 µg/mL) substantially decrease in E-cadherin 
expression at the 8-cell stage. Finally, our data also demonstrated that a relevant phthalate mixture 
(1 µg/mL) increased the number of embryos that had micronucleation at the 4-cell stage. 
Collectively, the data from this study suggests that exposure to a relevant phthalate mixture alters 
preimplantation embryo development at several different stages, alters protein expression, 
increases fragmentation, and micronucleation.  
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Exposure to a relevant phthalate mixture during preimplantation embryo development 
significantly decreased the overall development at several different stages at the higher dose 
treatment groups (0.01µg/mL, 0.1µg/mL, and 1µg/mL) compared to the control and vehicle 
control. Reduction of embryo development was first observed at the 8-cell stage, majority of the 
embryos dosed with the higher concentrations (0.01µg/mL, 0.1µg/mL, and 1µg/mL) were 
observed arrested at the 4-cell stage. At the 8-cell stage there was a significant increase in the 
percentage of embryos observed arrested in the 4-cell stage in treatment groups 0.1ug/mL (46.5%) 
and 1ug/mL (40.1%) compared to the control. Limited studies have shown that exposure to 
phthalates and other chemicals causes embryo arrest or developmental delay of embryos at several 
different stages [29, 42, 50]. The findings of the current studies suggest that chemical exposure at 
earlier stages of development may interfere with certain genes responsible for development. Our 
study also demonstrated that a low percentage of embryos exposed to higher doses (0.01µg/mL, 
0.1µg/mL, and 1µg/mL) were able to develop to later stages.  Although still significantly different 
from the control group, treatment groups (0.01µg/mL, 0.1µg/mL, and 1µg/mL) there was a slight 
increase of the total percentage of embryos that developed from the 8-cell stage to morula. This 
suggests that some embryos may have undergone developmental delay from the 4 to 8-cell stage, 
but somehow progressed to the morula stage. Lastly, our data demonstrated that a significantly 
low percentage of mixture-treated embryos are capable of progressing to the hatched blastocyst 
stage. These findings suggest that although the phthalate mixture significantly reduced 
preimplantation embryo development, embryos are not completely blocked. This is critical 
information, as previous studies have dosed dams with phthalates pre pregnancy and during 
pregnancy, which, observed reduced pregnancy, loss of pregnancy, abortion and reduced 
implantation [43, 44, 50, 51, 52]. Therefore, it is plausible that low percentage of embryos develop 
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to the hatched blastocyst stage and implant in the uterus. However, it may be possible that these 
embryos may encounter complications leading to loss of pregnancy, abortion and reduced 
implantation. Further investigation will be needed to determine these effects.  
Phthalate mixture exposure at the two higher doses (0.1µg/mL, and 1µg/mL) significantly 
increased overall fragmentation compared to the control group. Within both treatment groups, the 
degree of fragmentation of the embryo was relatively high with (>20%) overall fragmentation. 
During development, embryos undergo several rounds cleavage as the embryo progresses. Recent 
studies have shown that during the cleavage process, embryos can undergo fragmentation resulting 
in a decreased rate of blastocyst formation and implantation [53,54, 55]. Fragmentation may occur 
due to improper cleavage of cells, chromosome malfunction, or apoptosis [48,53]. Therefore, our 
findings suggest that the phthalate mixture may interfere with cleavage or interfere with 
chromosome functionality. Further investigation is needed to determine the cause of 
fragmentation. 
Our study demonstrated that exposure to a relevant phthalate mixture at the highest dose 
(1µg/mL) increased the percentage of embryos that had micronucleation at the 4-cell stage. 
However, statistically, our data indicated that there was no significant difference within the other 
treatment groups at the 4-cell stage. There was also no statistically significant difference of 
micronucleation at the 8-cell stage and the blastocyst stage as well compared to the control or 
vehicle. It is possible that an increased (n) would result in a significant statistical difference in the 
percentage of embryos that have micronucleation. Studies have shown that exposure to phthalates 
impaired the ability of DNA double-stranded break repair, leading to an apoptotic response, 
reduced survival, cell-cell communication and ion function [56,57]. Given the results of our study, 
it may be possible that exposure to a phthalate mixture causes genotoxic effects in earlier stages 
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of development, thus causing the occurrence of micronucleation in preimplantation embryos. 
Nonetheless, further investigation is needed to conclude these findings. Limitations of this study 
was RT-PCR, due to the limited number of embryos.  
Exposure to a relevant phthalate mixture increased the expression of Oct-4 at the 4-cell 
stage in the highest treatment group (1µg/mL). Due to the high percentage of embryos that 
underwent arrest and delay at the 4-cell stage, it was critical to determine whether the mixture 
altered protein expression, in particular, Oct-4.  Initially, we hypothesized that protein expression 
of Oct-4 would significantly decrease from the development observation. On the contrary, there 
was a marked increase of Oct-4 expression at the 4-cell stage within the highest treatment groups. 
Chu et al. [29] reported that preimplantation embryos exposed to MEHP resulted in increased 
expression Oct-4. They suggested that MEHP-exposed embryos may be involved in 2-cell and 4-
cell embryo development arrest through preventing activation of gene targets. Currently, limited 
studies further demonstrate the effects of increased expression of Oct-4 in the preimplantation 
embryo exposed to phthalates and potential genes targeted, resulting in cellular arrest or delay. 
Further studies will be needed to interpret what high expression of Oct-4 indicates in 4 cell 
embryos.  
 Exposure to a relevant phthalate mixture decreased the expression of E-cadherin at the 8-
cell stage in the three highest treatment groups (0.01µg/mL, 0.1µg/mL, and 1µg/mL). Embryos 
within these treatment groups had a low fluorescence intensity and an uneven distribution (which 
looked patchy) of E-cadherin compared to the control. Embryos which did have average E- 
cadherin intensity in treatments groups (0.01µg/mL, 0.1µg/mL, and 1µg/mL) compared to the 
control had blastomeres with an unusual wavy surface, further investigation will be needed to 
determine what this indicates. Studies have shown that that alterations of cadherins, decompacts 
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embryos, and prevents blastocyst formation [58, 59]. Also, embryos with reduced E-cadherin 
usually die as the cells will not undergo cellular differentiation [58,59]. Peña et al. [60] 
demonstrated that perinatal exposure to BPA decreased E-cadherin expression in preimplantation 
embryos and affected the viability of said embryos. Nonetheless, there are minimal studies on the 
effects of phthalates on E-cadherin on preimplantation embryos. 
Limited studies have suggested that phthalates interfere with several components which 
affect E-cadherin function in other cell and tissue types. Studies have shown that the presences of 
phthalates interfere with standard Ca+ functionality in both cell and tissue types [61, 62]. In order 
for E-cadherin to properly adhere to adjacent cells, Ca2+ must be present and stable [63, 64]. 
Therefore, it is possible that the phthalate mixture is interfering with Ca2+ and reducing the stability 
of the Ca2+ arms or signaling, thus reducing E-cadherin based adhesion. Other studies have also 
suggested that progesterone (P4) promotes E-cadherin expression and is inhibited by estradiol (E2) 
[65, 66], due to phthalates altering normal hormonal responses it is possible the phthalate mixture 
is altering P4 functionality leading to a more E2-dominant environment that promotes the reduction 
of P4 signaling, thus reducing E-cadherin function. Although these studies have suggested that 
phthalate exposure affects E-cadherin function, further investigation will be needed to conclude 
that a phthalate mixture indeed interferes with E-cadherin in preimplantation embryos at the 8-cell 
stage. 
The phthalate mixture did not affect the number of ICM and TE cells at the hatched 
blastocyst stage. Although the phthalate mixture had deleterious effects on preimplantation 
embryo development, there was a low percentage of embryos was able to hatch. Therefore, it was 
critical to determine whether the phthalate mixture altered the cell population of the ICM and TE. 
Generally, the total number of cells present in the mouse blastocyst range from 115-140 cells 
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depending on strain and age of mice [67, 68, 69]. Limited studies that have shown that exposure 
to a single EDC alters the cell population of the blastocyst. One study demonstrated that exposure 
to DBP and MBP decreased the number of cells in the blastocyst - TE cell lineage [69]. Although 
the data from our study demonstrated that exposure to a relevant phthalate mixture did not affect 
cell numbers of either the ICM or TE, it is critical to further investigate whether the mixture alters 
other critical genes necessary for implantation and fetal development. 
Culture medium exposed to the phthalate mixture did not cause any significant changes in 
the pH levels post-24 hours and 120 hours of incubation. Environmental pH is critical in the 
developmental success of preimplantation embryo(s). The ideal pH for proper development of 
preimplantation ranges from 7.2-7.4. [71, 72,73]. 
In conclusion, the data from this research shows that exposure to an environmentally 
relevant phthalate mixture induced a multitude of alterations at different stages of development 
effecting preimplantation embryo development. Specifically, exposure to the phthalate mixture 
affects preimplantation embryo development by causing cellular arrest/delay, altered protein 
expression, increased fragmentation, and increased micronucleation. This study provided some of 
the first information indicating the use of a phthalate mixture mimicking human exposure and 
examines the effects on preimplantation embryo development. However, this study did not provide 
mechanistic evaluation of the phthalate mixture induced effects. Therefore, future analyses are 
required to determine the underlying mechanisms of action of the phthalate mixture on 
preimplantation embryo development, specifically genetic pathway and signaling. Additionally, 
few studies have shown that single endocrine disrupting chemicals affects preimplantation embryo 
development at several different stages of the development, depending on dose levels and the 
particular endocrine disrupting chemicals being used [29, 59]; therefore, it is of great interest to 
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investigate if a mixture of phthalates could indeed induces genetic regulatory pathways and 





























3.5 Figures & Tables 
Figure 3.1. The Representative stages of preimplantation embryo development and development 
percentages. Representative embryos at the 2-cell stage of development (A and B). The graph 
shows the average percentage of embryos that developed to the 2-cell stage (C). There was no 
significant difference from the control group at the 2-cell stage. Representative embryos at the 8-
cell stage of development (D and E). The average percentage of embryos which developed to the 
8-cell stage (F). An asterisks (*) represents a significant difference from the control (p ≤ 0.05). 
Treatment groups 0.01 µg/mL (p≤0.0413), 0.1 µg/mL (p<0.0413), and 1 µg/mL (p < 0.0025). 
Table 1 shows the percentage of embryos delayed at the 4-cell stage. The percentage of embryos 
delayed at the 4-cell stage (G). Asterisks (*) represents a significant difference from the control 
(p<0.05), treatment groups 0.1 µg/mL (p ≤ 0.0004), and 1 µg/mL p ≤ 0.0025). Representative 
embryos at the morula stage (H and I). The average percentage of embryos which developed to 
the morula stage (J). Asterisks (*) represents a significant difference from the control (p<0.05). 
Treatment groups 0.01 µg/mL (p ≤ 0.0027), 0.1 µg/mL (p ≤ 0.0001), and 1 µg/mL (p ≤ 0.0005). 
Representative embryos at the blastocyst stage of development (K and L). The average percentage 
of which developed to the blastocyst stage. Asterisks (*) represents a significant difference from 
the control (p<0.05). Treatment groups 0.01 µg/mL (p ≤ 0.0266), 0.1 µg/mL (p ≤ 0.0001), and 1 
µg/mL (p ≤ 0.0002). Representative embryos at the hatched blastocyst stage (N and O). Asterisks 
(*) represents a significant difference from the control (p<0.05). Treatment groups 0.01 µg/mL 
(p ≤ 0.0182), 0.1 µg/mL (p ≤ 0.0007), and 1 µg/mL p ≤ 0.0001). (Q) is a representative graph of 
overall development from the 2-cell to hatched blastocyst stage. 
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Figure 3.1 (Cont.) 
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Figure 3.2. The effects of a phthalate mixture on embryo fragmentation.  Representative embryos 
which display fragmentation during development. (A) 2-cell, (B) 4-cell, (C) 8-cell. (D) The graph 
shows the average percentage of embryos which had some form of fragmentation. One-way 
ANOVA Multiple Comparison statistical analysis. Asterisks (*) represent a significant difference 
from control (p ≤ 0.05). (E). Treatment group 0.1ug/mL (p ≤ 0.0061), and 1ug/mL p ≤ 0.0043). (E) 
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Figure 3.3. The effects of a relevant phthalate mixture on Oct-4 expression at the 4-cell stage. (A) 
Representative embryo of the DMSO group expressing Oct-4. (B) Same embryo in an only with 
DAPI. (C) Representative embryo of 1ug/mL expressing Oct-4. (D) Same embryo in C only with 
DAPI. (E) The graph showing the average RFU intensity of Oct-4. One-way ANOVA Multiple 
Comparison statistical analysis. Asterisks (*) represent a significant difference from control 

































Figure 3.4. The effects of a relevant phthalate mixture on E-cadherin expression at the 8-cell stage.  
Representative embryos of each treatment group affect by phthalate exposure compared to the 
control group (A) Control, (B) 0.01µg/mL, (C) 0.1µg/mL and (D) 1µg/mL. (E) The graph showing 
the average RFU intensity of E-cadherin. One-way ANOVA Multiple Comparison statistical 
analysis. Asterisks (*) represent a significant difference from control (p ≤ 0.05).       (D). Treatment 
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Figure 3.5. The effects of a relevant phthalate mixture on E-cadherin expression at the Blastocyst 
stage.  Representative embryos of each treatment 1µg/mL (A). (B) The graph showing the average 
RFU intensity of E-cadherin. One-way ANOVA Multiple Comparison statistical analysis. 
Asterisks (*) represent a significant difference from control (p ≤ 0.05). There was no significant 
difference. 
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Figure 3.6. The effects of a relevant phthalate mixture on hatched blastocyst cell population-ICM 
and TE. (A) Representative embryos of each treatment 1µg/mL. Table 3.2 shows the average 
number of cells from each cell lineage and the ratio between the two cell types. One-way ANOVA 
Multiple Comparison statistical analysis. Asterisks (*) represent a significant difference from 



































Figure 3.7. The effects of a relevant phthalate mixture cause micronucleation. (A) Representative 
embryos of three different stages of development (A) 4-cell, (B) 8-cell, and (C) Blastocyst exposed 
to the phthalate mixture. (D) Graph shows percentage of embryos which had micronucleation at 
the 4-cell stage. Chi-square and Fisher Exact analysis was done. Asterisks (*) represent a 
significant difference from control (p ≤ 0.05). 1µg/mL (p ≤ 0.0031). (E)  Graph shows percentage 
of embryos which had micronucleation at the 8-cell stage. Chi-square and Fisher Exact analysis 
was (C). There was no significant difference. (F) Graphs shows percentage of blastocyst which 
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Chapter 4: Conclusion And Future Directions 
 
The goal of my doctoral dissertation was to investigate the effects of relevant doses of 
phthalates on the female reproductive system utilizing a mouse model. Phthalates are highly 
produced plasticizers as they are used routinely in a wide array of products, cosmetics, medical 
tubing, food containers, beverage containers, children’s toys, flooring, and clothing. Phthalates 
leach from these products that humans consume on a daily basis. Thus, phthalates are detected in 
human tissues and bodily fluids. Furthermore, phthalates have adverse effects on the reproductive 
system in both males and females. Phthalates negatively impact reproduction so severely that they 
are classified as a reproductive toxicant. This is of public concern. However, there are limited 
studies which have investigated the effects of relevant dose levels at environmental and 
occupational on the uterus. Furthermore, there are even fewer studies that have investigated the 
effects of a relevant phthalate mixture on preimplantation embryo development. 
Comprehending the effects of phthalates on uterine morphology and function, as well as 
preimplantation development, is critical because proper functionality of the uterus is essential for 
successful pregnancies. In addition, proper development of preimplantation embryos is crucial as 
interferences during the development phase can have catastrophic effects on embryo viability. 
Collectively, my studies demonstrated that both environmentally and occupationally relevant 
doses of DEHP has deleterious effects on uterine proliferation, blood vessels, and gland numbers. 
Also, my studies demonstrated that a relevant phthalate mixture negatively impacts 
preimplantation embryo development. Exposure to the mixture impacts development, increases 
fragmentation, increases Oct-4 protein expression, decreases E-cadherin expression and increases 
micronucleation of preimplantation embryos.     
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In Chapter 2, I quantified the impact of exposure to relevant environmental and 
occupational levels of DEHP on uterus of adult CD1 mice after 30 days. I first hypothesized that 
relevant levels of DEHP disrupt cellular proliferation of the uterus and alter morphological features 
in vivo. I found that exposure of adult female CD-1 mice to DEHP led to significant changes in the 
abundance of glands within endometrium that were dependent on the treatment dose of DEHP.  
The highest treatment group (200mg/kg/day) significantly increased the number of glands present, 
indicating that DEHP may act to stimulate uterine gland formation, perhaps through increased 
migration or proliferation of the glandular cells. In contrast, DEHP treatment groups at 
20µg/kg/day and 200µg/kg/day significantly decreased the numbers of proliferating cells in the 
luminal epithelium, suggesting that DEHP inhibited normal estrogen-regulated proliferation. The 
three highest doses of DEHP caused marked effects on the numbers of abnormally dilated blood 
vessels in the endometrium and also significantly increased stromal cell proliferation. DEHP had 
no significant morphological effect on the myometrium (inner and outer layer) or the height of the 
luminal epithelium. The results suggest that extended exposure to DEHP results in a progesterone-
dominant environment in the uterus, even though circulating P4 and E2 levels were not affected. 
Thus, chronic exposure to DEHP as an adult causes distinct changes in the endometrium that may 
negatively impact reproductive function.  Based off the finding from this study future studies 
should perform IHC and real-time PCR experiments to determine if implantation and receptivity 
markers (E-cadherin, MMPs, HoxA10, ect) are altered causing down-regulation or up-regulation 
due to exposure to DEHP.  Future studies should examine whether DEHP exposure reduces the 
height of pinopodes, thus altering endometrial receptivity and overall infertility. In addition, future 
studies should perform a time course experiment to determine if exposure to DEHP reduces the 
number of implantation sites at gestational day 5 and if hemorrhaging or resorption of the fetus 
121 
occur, therefore impacting overall fertility. Lastly future studies should investigate whether adult 
female mice exposed to DEHP for 30 days fetal outcome (weight, length and overall health) of 
pups.  
In chapter 3, I provided evidence that a relevant phthalate mixture directly altered 
preimplantation development and an abundance of marker proteins. I found that exposure of a 
relevant phthalate mixtures led to a significant change throughout several stages during 
preimplantation embryos development. The three highest groups 0.01µg/mL, 0.1µg/mL, and 
1µg/mL significantly decreased embryo development from the 8-cell stage to the hatched 
blastocyst, indicating that the phthalate mixture may act on critical developmental genes or perhaps 
it may interfere with chromosome separation. Indeed, a large percentage of embryos were found 
in the 4-cell stage when they should have progressed to the 8-cell stage, further suggesting the 
impact of the mixture on developmental genes. In contrast, treatment groups 0.1µg/mL and 
1µg/mL proved to cause increased fragmentation associated with a high degree of fragmentation, 
suggesting the mixture interferes with cleavage or creates an environment that induces an apoptotic 
response. The highest treatment groups, 1µg/mL, showed a marked increase of Oct-4 expression 
at the 4-cell stage. This was an unexpected outcome as we expected a decrease in Oct-4 due to the 
percentage of embryos that were observed in cellular arrest or had a delay in developmental. The 
three highest groups also showed a decreased in E-cadherin expression, suggesting the mixture is 
either interfering with the Ca2+ causing the calcium structures to become unstable, therefore 
interfering with cellular adhesion or the mixture is mimicking sex hormones inhibiting normal 
hormonal responses thus down-regulating E-cadherin expression. The highest treatment group 
,1µg/mL, increased the percentage of embryos that had micronucleation at the 4-cell stage. This 
may indicate that the mixture is indeed interfering with chromosomal separation which leads to 
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increased fragmentation during cleavage, interferes with embryo development. The mixture was 
shown to have no effects on E-cadherin abundance at the blastocyst stage. My study demonstrated 
the mixture had no effect on the number of ICM and TE cell numbers.  
Future studies should investigate the effects of the phthalate mixture on gene expression of key 
genes needed for a preimplantation embryo development. Considering that the mixture increased 
Oct-4 abundance at the 4-cell stage, several other co-activating and downstream genes should be 
critically investigated. For example, Sox2 should be investigated because it forms a complex with 
Oct-4 further maintaining pluripotency and other downstream networks. Furthermore, estrogen 
receptor α (ERα) should be studied as well. One study indicated that ERα is found in the nucleus 
of embryos and helps regulate gene expression, namely Oct-4. Considering that phthalates mimic 
sex steroids it may be possible that the mixture in acting on these receptors thus causing an increase 
in genetic response of Oct-4. Other future studies should perform to investigate estrogen levels as 
studies- in chapter 3 [65,66]- suggested that estrogen can suppress progesterone leading to the 
inhibition of E-cadherin.  In addition, future studies should examine if DNA methylation is altered 
thus, reducing the development of preimplantation embryos due to exposure of the phthalate 
mixture. Lastly, due to the limited number of embryos which developed to the blastocyst stage, 
future studies should preform embryo transfers at the blastocyst stage using surrogate mothers that 
have treated with the phthalate mixture and untreated mothers to determine whether implantation 
occurs.  
Overall, my doctoral dissertation indicates that environmentally and occupationally 
relevant phthalate doses disrupts female reproduction, affecting the uterus. In addition, exposure 
of a relevant phthalate mixture disrupts preimplantation embryo development. Adult female mice 
exposed to relevant doses of DEHP for 30 days affected cellular proliferation, increased the 
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number of dilated blood vessels, and increased the number of glands in the uterus. The data from 
this study suggests that exposure to a relevant dose of DEHP can have a negative impact on adult 
female reproductive health. Also, that a relevant phthalate mixture impact embryo development 

















Appendix A: Immunohistochemical Staining 
Immunohistochemical staining 
1. For ABC method: Proliferating Cell Nuclear Antigen (Use Mouse Kit)   ACTA2: Smooth Muscle 
(Use Rabbit Kit) 
2. All procedures are performed at room temperature unless specified 
3. Keep antibody solutions on ice. 
4. Do not allow sections to dry once you start staining. Incubation must be performed in a moist 
chamber. 
Day Procedure Time 
1 Deparaffinization and rehydration  
Wash in tap water  5 min 
Antigen retrieval in 0.01M citrate buffer or 1X Dako 
(make new citrate buffer each time/change Dako weekly) 
Boil for 20 min 
Cool down to room temperature  
Wash in 1X PBST on shaker 5 min 
Inactivation of endogenous peroxidase in 0.3% H2O2/Methanol 
(make new solution each time) 
15 min 
Wash in 1X PBST on shaker  5 min *3 
Encircle section with a PAP pen while rinsing in PBST 
(make sure draw big circles far from sections to prevent oil blocking) 
 
Blocking of non-specific binding in 5% normal serum and 1% BSA 60 min RT 
Reagent(s) Dilution Company 
Proliferating Cell Nuclear 
Antigen (PCNA) 
(1:500) Novus Biologicals., Littleton, CO 






DAKO Target Retrieval (1:10) Dako Denmark A/S, Demark 
3 3'-dimethoxybenzidine (DAB)  Vector Laboratories, Inc. Burlingame 
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(never let sections dry out) 
Incubation in the primary antibody diluted in 1%BSA/PBST (PCNA)   
1:500 
Overnight at 4°C 
   
2 Rinse in PBST on shaker 5 min * 3  
Incubation in biotinylated secondary antibody in 1%BSA/PBST       60 min RT 
Prepare ABC solution in 1%BSA/PBST 30 min before use 
(PBS:A:B=50:1:1) 
 
Rinse in PBST on shaker 5 min * 3 
Incubation in ABC solution at RT  30 min 
Rinse in PBST on shaker 5 min * 3 
DAB reaction (watch under scope for time needed to change color, time 
varies to different AB) 
~  30 sec 
Stop DAB reaction in tap water 10 min 
Counterstaining in hematoxylin (filter hematoxylin) 2 min 
Wash in tap water (only tap water, not DI water) >10 min 




Deparaffinzation and rehydration: Dehydration and clearing 
Xylene 1: 5 min 70% Ethanol: 1 min 
Xylene 2: 5 min 80% Ethanol: 1 min 
Xylene 3 (clean): 5 min 90% Ethanol: 1 min 
100% Ethanol: 5 min 100% Ethanol: 1 min 
100% Ethanol: 5 min 100% Ethanol: 1 min 
90% Ethanol: 5 min Xylene 1: 1 min 
80% Ethanol: 5 min Xylene 2: 1 min 




Appendix B: Embryo Culture Reagents 
Stocks •  
Start with approximately half the final volume of MilliQ H2O in a beaker with stir bar                              
Add reagents                                                                                                                                                              
Pour into the appropriate volumetric flask                                                                                                          
Rinse beaker ≥3 times with MilliQ H2O                                                                                                                   
QS to final volume with MilliQ H2O                                                                                                                     
Filter (0.22 µm)                                                                                                                                                             
Store at 5 ºC for 1 month 
Optimized Embryo Culture Medium (OEC) Base 
Reagent  MW Final mM g/100ml 
NaCl S6191 58.44 100 5.8440 
KCl 60128 74.55 5.0 0.3728 
KH2PO4 60218 136.1 0.50 0.0681 






Glutagro 25-015-CI cellgro/Mediatech 
Non-Essential Amino Acids (100x, MEM) 25-025-Cl cellgro/Mediatech 
Essential Amino Acids w/o glutamine 25-030-Cl cellgro/Mediatech 
AlbIX Recombinant Human Serum Albumin (100 mg/ml)  Novozymes 








Appendix C:  Phthalate Mixture Protocol 
Make new batch of mixture every 3 months. 
1. Obtain one autoclaved glass 12ml amber vial. 
2. Obtain pipettes and pipette tips (200 µl and 100 µl).  
3. Change pipette tip between each phthalate chemical. 
Phthalate Mixture 
Phthalates Volume Percentage 
Diethyl Phthalate (DEP) 157.00 µl 35% 
Di (2-ethylhexyl) Phthalate (DEHP) 106.50 µl 21% 
Di-isononyl Phthalate (DiNP) 77.50 µl 15% 
Di-n-butyl Phthalate (DBP) 71.12 µl 15% 
Di-isobutyl Phthalate (DiBP) 43.30 µl 8% 
Benzyl butyl Phthalate (BBzP) 23.20 µl 5% 
   
Total 478.62 µl 99% 
 
4. Dispense the appropriate volume into vial and thoroughly homogenize the phthalates for 30 secs. 
5. Make a 100 µl/mL stock  
1. Dimethyl Sulfoxide (DMSO): 130.82 µl. 










100µg/ mL 10µg/ mL 1µg/ mL 0.1µg/ mL 0.01µg/ mL 0.001µg/ mL 
Stock of 
Phthalate Mix 90µl DMSO 
90µl DMSO 90µl DMSO 90µl DMSO 
90µl DMSO 
10µl  10µl  10µl  10µl  10µl  
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6. Make 10µl aliquiot of each respective concentration (place 1µl/mL, 0.1µl/mL, 0.01µl/mL 






























Appendix D: Preparing Embryo Culture Plates And Collection Tubes 
*Change pipette tips between each concentration* 
1. Write type of medium, date, and initials on all tubes and dishes. 
 
2. Add 1mL of LifeGolbal LGGG-100 culture medium into six autoclaved 3 mL glass tubes. *do 
not use glass tubes that have been washed with detergents* 
 
3. Add 0.75 µl of the appropriate concentrations (DMSO (0.075%), 0.001 µg/mL, 0.01 µg/mL, 0.1 
µg/mL, or 1µg/mL) to designated glass tube and thoroughly mixed for 30 secs. *mix by pipetting 
or on vortex shaker*.  
 
4. Prepare wash dishes in Falcon 35 mm center-well dishes for each treatment group and cover with 
mineral oil. 
1. Pipette 500 µl of the appropriate mixture into the center of a Falcon 35 mm center-well 
dish.  
2. Add 500 µl of mineral oil on top of each treatment group. 
 
5. Prepare embryo culture dishes in Falcon 35 mm dishes for each treatment group. Every group 
should have its own plate. 
1. Pipette 5-6 drops at 20 µl of the respective mixture on to each plate and covered with 9 mL 
of mineral oil. 
 
6. Prepare collection/handling medium in 14mL Falcon snap tubes (352057). 
1. Add 9.5 mL optimized (3-(N-morpholino) propanesulfonic acid) (OMOPS) into a Falcon 
14 mL tube.   
2. Add 500 µl (5%) fetal bovine serum (FBS) and thoroughly mix tube for 30 secs. Prepare 
~10 ml per 3-4 females. 
 
7.  Place dishes (culture and washes) and handling medium in Thermo Fisher 8000 WJ CO2 incubator 





Appendix E: Collection of One Cell Embryos 
 
1. Preperation of hormones preganat mare serun gonadotrhopin (PMSG) and of human chorionic 
gonadotropin (hCG). 
1. PMSG (1000 I.U.), Calbiochem Cat #367222 
2. Dilute with autoclave PBS or DI water to 50 I.U./mL 
3. Aliquot 500 µl per tube place in -20˚ until needed 
 
2. Prepare human chorionic gonadotropin (hCG). 
1. hCG, Calbiochem Cat#230734 
2. Dilute with autoclave PBS or DI water to 50 I.U./mL 
3. Aliquot 500 µl per tube place in -20˚ until needed 
 
3. Prepare hyaluronidae (aids in removal of cumulus cell) 
1. Dilute to 10 mg/mL with 3 mL of PBS or DI water. 
2. Aliquot 30 µl in sterile 0.5 mL tubes and store at -80˚C 
3. Use 5 µl of this stock per 100 µl of OMOPS = 500 µg/mL   
    
4. Hormone injections 
1. Inject female each mouse with 6 I.U. (120 µl) of PMSG intraperitoneally (IP) between 
3:30 pm and 4:00 pm.   
2. Inject hCG 6 I.U. (120 µl) 45-46 hours after PMSG to avoid a possible endogenous LH 
surge at 4:00 pm. 
3. Place one female with an intact, fertile male immediately after injection of hCG. Always 
place female in male cage. 
 
5. Obtain collection/handling medium and supplies 
1. OMOPS medium. 
2. Thaw one aliquot of hyaluronidase immediately before use. 
3. 1 or 2 forceps (clean with 70% EtOH). 
4. 35 mm center-well dishes (do not add OMOPS until just before use); 
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6. Collection of one cell embryos. Check vaginal plug at 8-8:50 am as plugs will dissolve Remove 
females with plugs and transfer to an empty cage. Multiple plugged females can be housed together. 
 
7.  Sacrificed females at 10:00 am collect and ovaries oviducts, and uteri were placed into OMOPS 
 
8. Under Olympus SZX12 dissecting scope, pour contents including medium into dish on slide 
warmer. Puncture the ampulla of all uterine horns to release the one cell embryo into OMOPS. All 
embryos are pooled at this step. If necessary, use a small pulled glass pipet to remove cumulus 
cells. 
 
9. If necessary, hyaluronidase can be used to facilitate cumulus cell removal. Add 50 µl hyaluronidase 
and aspirate one cell embryos for 30 sec to one minute. Using pulled glass pipet immediately 
transfer embryos to a new center well dish containing OMOPS to stop reaction. Wash the embryos 
4 to 5 more times to ensure reactions has stopped and cumulus cell are removed.  
 
10. In the last OMOPS wash count the number of embryos, only used high quality (fertilized, polar 
bodies, nuclei and intact zona pellucida) embryos for culture. Wash quality embryos in the 
respective treatment groups (control, DMSO, 0.001 µg/mL, 0.01 µg/mL, 0.1 µg/mL, or 1µg/mL) 
before being placed in culture. Place no more than ten embryos per droplet. Placed in the incubator 
















Appendix F: Immunofluresces staining and Measurement of Protein Expression 
Solutions: Make new every month 
Holding media: 
1. 50 ml PBS + 0.25 g BSA (0.5%) 
 
Washing buffer (WB):  
2. 500 ml PBS + 500 µl Triton X-100 (0.1%) + 0.5 g PVP (0.1%) 
 (PVP is poly-vinyl-pyrrolidone from Sigma PVP40 CAS#9003-39-8) 
 
Permeabilization Buffer (PB): 
3. 50 ml PBS + 500 µl Triton X-100 (1%) 
 
Blocking (BB):  
4. 50 ml PBS + 50 µl Triton X-100 (0.1%) + 0.5 g BSA (1.0%) + 0.3754 Glycine (0.1 M) 
For each replicate, put 450 µl BB in a well and add 50 µl Horse Serum. 
 
Antibody Buffer (AbB):  
5. 50 ml PBS + 50 µl Triton X-100 (0.1%) + 0.5 g BSA (1%) 
 
Antibodies:  
Primaries: - Anti-Oct4 rabbit mAB (Cell Signaling - D6C8T) 
                    100 µl | Suggested dilution 1:800 | Do not aliquot 
- Anti-CDX2 mouse monoclonal antibody (Biogenex MU392A-100 (sample) 
                    100 µl | Suggested dilution 1:300 | Shipped with a diluent (HK941-04K) 
-Anti-E-cadherin goat polyclonal (R&D Systems AF748) 
 100 µl ǀ Suggested dilution 1:100. 
Secondaries: - CY3 donkey anti-rabbit (555 nm)  
                        Jackson ImmunoResearch 711-165-152 | Suggested dilution 1:500 
          - CY5 donkey anti-mouse (690 nm)  
            Jackson ImmunoResearch 715-175-151 | Suggested dilution 1:400 
                    - Alexa Fluor 488  
(Jackson Immuno Research 715-545-150) ǀ Suggested dilution 1:100 
 
FIXATION            
1. Prepare fresh 4% paraformaldehyde 
2. Fix embryos by incubating in 4% paraformaldehyde for 20 minutes at room temperature. 
3. Transfer embryos to Holding Media (cover drops/wells with oil) and maintain at 4ºC until staining. 
 
Day 1 Procedure Time  Notes 
 Wash in Washing Buffer 3x 10 minutes   






Day 2 Procedure Time  Notes 
 Wash in Washing Buffer 3x 10 minutes   
 Incubate with secondary antibodies: 
CY3 donkey anti-rabbit  
        (dilution 1:500) 
CY5 donkey anti-mouse  
        (dilution 1:400) 
Make one solution with both secondaries. Put 
200 µl/well of that solution and transfer the 
embryos to the well. 
2 hours  
at room 
temperature 
Cover with foil. Protect from light 
now and all subsequent steps! 
 Wash in Antibody Buffer 2x 20 minutes  
 Wash in Washing Buffer 1 hour  
 Incubate with DAPI   30 minutes at 
dark at room 
temperature. 
use 2 drops of mounting media 
containing DAPI (from Vector) per 
well. Place the embryos in those wells. 
 Mount embryos in a 35 mm Glass bottom dish 
with 14 mm micro-well. Make 1 
dish/treatment (all embryos from same treat 
can be together) 
 Put 80 µl of mineral oil in the center. 
Add 10-20 µl of mounting media with 
the embryos on top of the oil, in the 
center 
 Coverslip with the help of a curved forceps. 
 Keep in at 4ºC in the dark for 24-48 hours before imaging (in a box inside the fridge). 
 
 Wash in Washing Buffer 10 minutes  
 Incubate in Blocking Buffer 2 hours 450 µl of blocking buffer + 50 µl of 
donkey serum/well 
 Wash in Washing Buffer 25 minutes  
 Incubate with primary antibody: 
anti-Oct-4 antibody (dilution 1:800) 
anti-CDX-2 antibody (dilution 1:300) made 
with diluent  
Overnight  
at 4oC 
Put 125 µl of each antibody solution 
per well (total 250 µl/well). Transfer 
embryos to wells. Wrapped 6-well dish 
in parafilm and put inside the fridge 
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OCT-4 should show green → specific for inner cell mass 
CDX-2 should show red → specific for trophectoderm 





After obtaining image of flourescenent embryo save image as a czi.file “raw image”. Once saved image 
should be reopened in Zen blue software to ensure that the image can be viewed on different z-positions. 
Turn off the DAPI channel and change the green channl to light gray. Start at z-position 10 (blastocyst). 
Click the profile tool, then select the pointer and drag the over the diameter of the embryo. Measure the 
intensity point then average the the total intensity of each plane. Repeat this procudere over the entire 
embryo every 10 increments. 
 
 
 
 
 
 
 
 
 
 
 
 
